Filed Pursuant to Rule 424(b)(2)
Registration No. 333-208330
The information in this preliminary prospectus supplement is
not complete and may be changed. This preliminary prospectus supplement is not an offer to sell nor does it seek an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.
Subject To Completion, Dated February 7,
2017
PROSPECTUS SUPPLEMENT
(To
Prospectus dated December 22, 2015)
Shares of Common Stock
Warrants to
Purchase Shares of Common Stock
We are offering shares of our
common stock and warrants to purchase up to shares of our common stock at an exercise price of $
per whole share of common stock. The shares of common stock and warrants will be sold in units, with each unit consisting of one share of common stock
and a warrant to purchase of a share of common stock. Each unit will be sold at a price of
$ per unit. The shares of common stock and warrants will be mandatorily separable immediately upon issuance.
Our common stock is listed on The NASDAQ Capital Market under the symbol GALE. On February 6, 2017 the last reported sale price of our
common stock on The NASDAQ Capital Market was $1.41 per share.
The warrants are not and will not be listed for trading on The NASDAQ Capital
Market, or any other securities exchange or nationally recognized trading system. There is no market through which the warrants may be sold, and purchasers may not be able to resell the warrants purchased under this prospectus supplement. This may
affect the pricing of the warrants in the secondary market, the transparency and availability of trading prices, and the liquidity of the warrants.
Investing in our securities involves a high degree of risk. Please read
Risk Factors
beginning on page S-13 of
this prospectus supplement and on page 1 of the accompanying prospectus and the documents incorporated by reference in this prospectus supplement and the accompanying prospectus.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this
prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
|
|
|
|
|
|
|
|
|
|
|
Per Unit
|
|
|
Total
|
|
Price to the public
|
|
$
|
|
|
|
$
|
|
|
Underwriting discounts and commissions(1)
|
|
$
|
|
|
|
$
|
|
|
Proceeds, before expenses, to us
|
|
$
|
|
|
|
$
|
|
|
|
(1)
|
For additional information about the expenses for which we have agreed to reimburse the underwriter in connection with this offering, see Underwriting beginning on page S-35 of this prospectus supplement
|
The underwriter expects to deliver the units on or about February ,
2017.
CANACCORD GENUITY
The date of this prospectus supplement is February , 2017.
TABLE OF CONTENTS
Prospectus Supplement
Prospectus
i
ABOUT THIS PROSPECTUS SUPPLEMENT
This prospectus supplement is part of the registration statement on Form S-3 (File No. 333-208330) that we filed with the Securities and
Exchange Commission, or the SEC, using a shelf registration process to register sales of our securities under the Securities Act of 1933, as amended, or the Securities Act. Unless otherwise indicated, information relating to our stock
price is the price as of a specified date or period and only reflects our November 2016 reverse stock split for periods subsequent to November 11, 2016. This document consists of two parts. The first part is this prospectus supplement, including the
documents incorporated by reference, which describes the specific terms of this offering. The second part is the accompanying prospectus filed with the SEC as part of the registration statement that was declared effective by the SEC on
December 22, 2015, including the documents incorporated by reference, that gives more general information, some of which may not apply to this offering. Generally, when we refer only to the prospectus, we are referring to both parts
combined. This prospectus supplement may add to, update or change information in the accompanying prospectus and the documents incorporated by reference into this prospectus supplement or the accompanying prospectus.
We sometimes collectively refer to the shares of common stock and warrants offered hereby and the shares of common stock underlying the
warrants as the securities.
If information in this prospectus supplement is inconsistent with any document incorporated by
reference that was filed with the SEC before the date of this prospectus supplement, you should rely on this prospectus supplement. This prospectus supplement, the accompanying prospectus and the documents incorporated into each by reference include
important information about us, the securities being offered and other information you should know before investing in our securities. You should also read and consider information in the documents to which we have referred you in the section of
this prospectus entitled Where You Can Find More Information.
You should rely only on this prospectus supplement, the
accompanying prospectus and the information incorporated or deemed to be incorporated by reference in this prospectus supplement and the accompanying prospectus. We and the underwriters have not authorized anyone to provide you with information that
is in addition to or different from that contained or incorporated by reference in this prospectus supplement and the accompanying prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This
prospectus supplement, the accompanying prospectus and any related free writing prospectus do not constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such
offer or solicitation in such jurisdiction. You should not assume that the information contained or incorporated by reference in this prospectus supplement or the accompanying prospectus is accurate as of any date other than as of the date of this
prospectus supplement or the accompanying prospectus, as the case may be, or in the case of the documents incorporated by reference, the date of such documents regardless of the time of delivery of this prospectus supplement and the accompanying
prospectus or any sale of our securities. Our business, financial condition, liquidity, results of operations and prospects may have changed since those dates.
We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document
that is incorporated by reference into this prospectus supplement or the accompanying prospectus were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to
such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and
covenants should not be relied on as accurately representing the current state of our affairs.
The industry and market data contained or
incorporated by reference in this prospectus supplement and the accompanying prospectus are based either on our managements own estimates or on independent industry publications, reports by market research firms or other published independent
sources. Unless otherwise indicated, all information contained or incorporated by reference in this prospectus supplement and the accompanying prospectus concerning our industry in general or any segment thereof, including information regarding our
general expectations and market opportunity, is based on managements estimates using internal data, data from industry related publications, consumer research and marketing studies and other externally obtained data.
ii
PROSPECTUS SUPPLEMENT SUMMARY
This summary highlights selected information appearing elsewhere in this prospectus supplement or in the accompanying prospectus or
incorporated by reference into this prospectus supplement and the accompanying prospectus and does not contain all of the information that may be important to you or that you should consider before investing in our securities. Before making an
investment decision, you should read this prospectus supplement, the accompanying prospectus and the information incorporated by reference in this prospectus supplement and the accompanying prospectus in their entirety, including Risk
Factors beginning on page S-13 of this prospectus supplement.
About Galena
Overview
Galena Biopharma, Inc.
(we, us, our, Galena or the Company) is a biopharmaceutical company developing hematology and oncology therapeutics that address unmet medical needs. The Companys pipeline consists of
multiple mid- to late-stage clinical assets, including our hematology asset, GALE-401, and our novel cancer immunotherapy programs including NeuVax (nelipepimut-S), GALE-301 and GALE-302. GALE-401 is a controlled release version of the
approved drug anagrelide for the treatment of elevated platelets in patients with myeloproliferative neoplasms. GALE- 401 has completed a Phase 2 clinical trial and we plan to advance the asset into a pivotal trial in patients with essential
thrombocythemia (ET). NeuVax is currently in multiple investigator-sponsored Phase 2 clinical trials. GALE-301 and GALE-302 have completed early stage trials in ovarian, endometrial and breast cancers.
We are seeking to build value for shareholders through pursuit of the following objectives:
Develop hematology and oncology assets through clinical development with a focus in areas of unmet medical need. Our hematology asset
is targeting the treatment of patients with ET to reduce elevated platelet counts. Our immunotherapy programs are currently targeting two key areas: secondary prevention intended to significantly decrease the risk of disease recurrence in breast,
gastric, and ovarian cancers; and primary prevention intended to prevent ductal carcinoma in situ (DCIS) from becoming invasive breast cancer.
Evaluating strategic alternatives that may include continuing to advance the clinical programs as a stand-alone entity, a sale of the
company, a business combination, merger or reverse merger, and a license or other disposition of corporate assets of the company.
Expand our development pipeline by enhancing the clinical and geographic footprint of our technologies.
Leverage partnerships and
collaborations, as well as investigator-sponsored trial arrangements, to maximize the scope of potential clinical opportunities in a cost effective and efficient manner.
S-1
The chart below summarizes the current status of our clinical development pipeline:
Hematology
GALE-401 (Anagrelide Controlled Release)
GALE-401 contains the active ingredient anagrelide, an FDA-approved product, for the treatment of patients with myeloproliferative neoplasms
(MPNs) to lower abnormally elevated platelet levels. The currently available immediate release (IR) version of anagrelide causes adverse events that are believed to be dose and plasma concentration dependent, and may limit
the use of the IR version of the drug. Therefore, reducing the maximum concentration (C
max
) and increasing the half-life of the drug is hypothesized to reduce the side effects,
while preserving the efficacy, potentially allowing a broader use of the drug.
Multiple Phase 1 studies in 98 healthy subjects have shown
GALE-401 reduces the C
max
of anagrelide and increases the half-life following oral administration, appears to be well tolerated at the doses administered, and to be capable of reducing platelet
levels effectively. The Phase 1 program provided the desired PK/PD (pharmacokinetic/pharmacodynamic) profile to enable the initiation of the Phase 2 proof-of-concept trial. The Phase 2, open label, single arm, proof-of concept trial enrolled 18
patients in the United States for the treatment of thrombocytosis, or elevated platelet counts, in patients with MPNs. Final safety and efficacy data from this Phase 2 trial were presented in December 2015 and demonstrated a prolonged clinical
benefit with a potentially improved safety profile.
We have analyzed our data and the treatment landscape for MPNs, with a current focus
on Essential Thrombocythemia (ET). We plan to advance GALE-401 into a Phase 3 clinical trial in patients who are intolerant or resistant to hydroxyurea. The trial will compare GALE-401 (drug arm) versus best available therapy (BAT) to
include a sizable population of patients treated with anagrelide IR. After a productive meeting with the U.S. Food and Drug Administration (FDA) in December 2016, we have confirmed that the GALE-401 development program is appropriate for a New Drug
Application (NDA) filing using the 505(b)(2) regulatory pathway.
Essential Thrombocythemia is a myeloproliferative blood disorder, and is
characterized by the overproduction of platelets in the bone marrow. Elevated platelets alter the normal process of blood coagulation and can lead to thromboembolic events. About a third of patients are asymptomatic at the time of diagnosis.
However, many patients develop symptoms during the course of the disease that affect the quality of life.
S-2
Novel Cancer Immunotherapies
Our targeted cancer immunotherapy approach is currently based upon two key areas: preventing secondary recurrence of cancer, which is becoming
increasingly important as the number of cancer survivors continues to grow; and, primary prevention intended to prevent ductal carcinoma
in situ
(DCIS) from becoming invasive breast cancer. Once a patients tumor becomes metastatic, the
outcome is often fatal, making the prevention of recurrence a potentially critical component of overall patient care. Our secondary recurrence programs primarily target patients in the adjuvant (after-surgery) setting who have relatively healthy
immune systems, but may still have residual disease. Minimal residual disease, or micrometastasis, that are undetectable by current radiographic scanning technologies, can result in disease recurrence.
Our therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating
factor (rhGM-CSF), and work by harnessing the patients own immune system to seek out and attack any residual cancer cells. Using peptide immunogens has many potential clinical advantages, including a favorable safety profile, since these drugs
may lack the toxicities typical of most cancer therapies. They also have the potential to induce immunologic memory and provide long-lasting protection with a convenient, intradermal mode of delivery.
NeuVax (nelipepimut-S)
NeuVax (nelipepimut-S) is a cancer immunotherapy targeting human epidermal growth factor receptor (HER2) expressing cancers. NeuVax is
the immunodominant nonapeptide derived from the extracellular domain of the HER2 protein, a well-established and validated target for therapeutic intervention in breast and gastric carcinomas. The NeuVax vaccine is combined with GM-CSF for injection
under the skin, or intradermal administration. Data has shown that an increased presence of circulating tumor cells (CTCs) may predict Disease Free Survival (DFS) and Overall Survival (OS) suggesting a presence of isolated micrometastases, not
detectable clinically, but, over time, can lead to recurrence, most often in distant sites. After binding to the specific HLA molecules on antigen presenting cells, the nelipepimut-S sequence stimulates specific cytotoxic T lymphocytes, or CTLs,
causing significant clonal expansion. These activated CTLs recognize, neutralize and destroy, through cell lysis, HER2 expressing cancer cells, including occult cancer cells and micrometastatic foci. The nelipepimut immune response can also generate
CTLs to other immunogenic peptides through inter- and intra-antigenic epitope spreading.
Breast Cancer
: According to the National
Cancer Institute (NCI), over 230,000 women in the U.S. are diagnosed with breast cancer annually. While improved diagnostics and targeted therapies have decreased breast cancer mortality in the U.S., metastatic breast cancer remains incurable.
Approximately 75% to 80% of breast cancer patients have tissue test positive for some increased amount of the HER2 receptor, which is associated with disease progression and decreased survival. Only approximately 20% to 30% of all breast cancer
patients-those with HER2 immunohistochemistry (IHC) 3+ disease, or IHC 2+ and fluorescence in situ hybridization (FISH) amplified-have a HER2 directed, approved treatment option available after their initial standard of care. This leaves the
majority of breast cancer patients with low-to-intermediate HER2 expression (IHC 1+, 2+) ineligible for therapy and without an effective targeted treatment option to prevent cancer recurrence.
We currently have two investigator-sponsored trials (IST) ongoing with NeuVax in combination with trastuzumab (Herceptin®;
Genentech/Roche). The combination of trastuzumab and NeuVax has been shown pre-clinically and in a pilot study to be synergistic. Our Phase 2b clinical trial is a randomized, multicenter, investigator-sponsored, 300 patient study enrolling HER2 1+
and 2+, HLA A2+, A3+, A24 and/or A26, node positive, and high-risk node negative patients. Eligible patients are randomized to receive NeuVax + GM-CSF + trastuzumab or trastuzumab + GM-CSF alone. The primary endpoint of the study is disease-free
survival. Genentech/Roche is providing the trastuzumab and partial funding for this trial. Data presented in October 2016 demonstrated that this novel combination of trastuzumab and NeuVax with HER2 low-expressing patients is well tolerated and the
cardiac effects of trastuzumab are not impacted by the addition of NeuVax. In February 2017 , the Data Safety Monitoring Board (DSMB) reported that there were no safety concerns with the trial and the trial is not futile. The recommendation from the
DSMB was to continue the trial with one revision to the statistical analysis plan regarding the timing of the pre-specified interim analysis. Given the lengthy duration of enrollment for the trial, the DSMB determined that the pre-specified interim
efficacy analysis be moved up from 12 months to 6 months after the last patient is enrolled. Completion of enrollment is expected in the second quarter of 2017; therefore, the DSMB expects to perform the interim efficacy analysis near the end of
2017.
Our second IST combination trial is a Phase 2 in HER2 3+ breast cancer patients who have completed neoadjuvant therapy with an
approved regimen that includes trastuzumab and fail to achieve a pathological complete response, meaning they have microscopic evidence of residual disease and are therefore at an increased risk of disease recurrence. This multi-center, prospective,
randomized, single-blinded Phase 2 trial is enrolling approximately 100 patients with a diagnosis of HER2 3+ breast cancer who are HLA A2+ or HLA
S-3
A3+ and are determined to be at high-risk for recurrence. High-risk is defined as having received neoadjuvant therapy with an approved regimen that includes trastuzumab but not obtaining a
pathological complete response at surgery, or those who undergo surgery as a first intervention and are found to be pathologically node-positive. These high-risk patients are known to have higher recurrence rates than other HER2 3+ breast cancer
patients. Eligible patients will be randomized to receive NeuVax + GM-CSF + trastuzumab or trastuzumab + GM-CSF alone. The primary endpoint of the study is disease-free survival. Funding for this trial was awarded through the Congressionally
Directed Medical Research Program (CDMRP), funded through the Department of Defense (DoD), via a Breast Cancer Research Program (BCRP) Breakthrough Award. In February 2017, the Data Safety Monitoring Board (DSMB) reported that there were no safety
concerns with the trial and the trial is not futile. The pre-specified interim safety analysis was also completed on n=50 patients and demonstrated that the agent is well tolerated with no increased cardiotoxicity associated with giving NeuVax
in combination with trastuzumab. The recommendation from the DSMB was to continue the HER2 3+ trial unmodified.
A Phase 2 trial clinical
with NeuVax as a single agent in patients with ductal carcinoma
in situ
, or DCIS, is open for enrollment. The trial is being run in collaboration with the NCI, potentially positioning NeuVax as a treatment for earlier stage disease. The trial
has an immunological endpoint evaluating NeuVax peptide-specific cytotoxic T lymphocyte (CTL; CD8+ T-cell) response in vaccinated patients. DCIS is defined by the NCI as a noninvasive condition in which abnormal cells are found in the lining of a
breast duct, and.the abnormal cells have not spread outside the duct to other tissues in the breast. DCIS is the most common type of breast cancer. In some cases, DCIS may become invasive cancer and spread to other tissues, and at this time, there
is no way to know which lesions could become invasive. Current treatment options for DCIS include breast-conserving surgery and radiation therapy with or without tamoxifen, breast-conserving surgery without radiation therapy, or total mastectomy
with or without tamoxifen. According to the American Cancer Society, in 2015 there were over 60,000 diagnoses of DCIS.
On June 27,
2016, the Independent Data Monitoring Committee, or IDMC, recommended that the Phase 3 PRESENT (
P
revention of
R
ecurrence in
E
arly-
S
tage, Node- Positive Breast Cancer with Low to Intermediate HER2
E
xpression with
NeuVax T
reatment) clinical trial be stopped for futility. The PRESENT trial was stopped, and we initiated an investigation into the causes of the recommendation. Our analysis of the data showed that there was a separation of the curves,
albeit not statistically significant, with the control arm performing better than expected and the NeuVax arm performing consistent with our protocol assumptions for the control group. Because the study was deemed futile, we closed the PRESENT
trial, and we expect to present the data at a future medical conference.
Gastric Cancer: According to the NCI, gastric (stomach) cancer
is a disease in which malignant (cancer) cells form in the lining of the stomach. Almost all gastric cancers are adenocarcinomas (cancers that begin in cells that make and release mucus and other fluids). Other types of gastric cancer are
gastrointestinal carcinoid tumors, gastrointestinal stromal tumors, and lymphomas. Infection with bacteria called Helicobacter pylori (H. pylori) is thought to be the cause of gastric cancer and age, diet, and stomach disease can affect the risk of
developing gastric cancer. Gastric cancer is often diagnosed at an advanced stage because there are no early signs or symptoms, and is the second-most common cancer among males and third-most common among females in Asia and worldwide with over
63,000 new cases a year in India, where an initial clinical trial of NeuVax is planned. Overexpression of the HER2 receptor occurs in approximately 20% of gastric and gastro-esophageal junction adenocarcinomas, predominantly those of the intestinal
type. Overall, without regard to the stage of cancer, only approximately 28% of patients with stomach cancer live at least five years following diagnosis and new adjuvant treatments are needed to prevent disease recurrence. We currently have an
agreement with Dr. Reddys Laboratories to conduct a Phase 2 investigational study in gastric cancer in India.
GALE-301 AND GALE-302
Our second immunotherapy franchise targets folate binding protein (FBP) receptor-alpha. FBP is a well-validated therapeutic
target that is highly over-express in ovarian, endometrial and breast cancers, and is the source of immunogenic peptides that can stimulate cytotoxic T lymphocytes (CTLs) to recognize and destroy FBP-expressing cancer cells. Current treatments after
surgery for these diseases are principally with platinum based chemotherapeutic agents. These patients suffer a high recurrence rate and most relapse with an extremely poor prognosis. GALE-301 and GALE-302 are immunogenic peptides that consist of a
peptide derived from FBP combined with GM-CSF for the prevention of cancer recurrence in the adjuvant setting. GALE-301 is the E39 peptide, while GALE-302 is an attenuated version of this peptide, known as E39. Two early stage clinical trials
have been completed with our FBP peptides in ovarian, endometrial, and breast cancers. In June 2016, the U.S. Food and Drug Administration (FDA) granted two orphan-drug designations for the treatment (including prevention of recurrence) of ovarian
cancer: one for GALE-301 (E39), and one for GALE-301 (E39) and GALE-302 (E39).
S-4
Ovarian Cancer
: According to the NCI Surveillance, Epidemiology, and End Results
(SEER) Program, new cases of ovarian cancer occur at an annual rate of 11.9 per 100,000 women in the U.S., with an estimated 22,280 new cases and 14,240 deaths in 2016. Approximately 46.2% of ovarian cancer patients are expected to survive five
years after diagnosis. Approximately 1.3% of women will be diagnosed with ovarian cancer at some point during their lifetime (2011 - 2013 data). The prevalence data from 2013 showed an estimated 195,767 women living with ovarian cancer in the United
States. Due to the lack of specific symptoms, the majority of ovarian cancer patients are diagnosed at later stages of the disease, with an estimated 80% of women presenting with advanced-stage (III or IV) disease. These patients have their tumors
routinely surgically debulked to minimal residual disease, and then are treated with platinum- and/or taxane-based chemotherapy. While many patients respond to this treatment regimen and become clinically free-of-disease, the majority of these
patients will relapse. Depending upon their level of residual disease, the risk for recurrence after completion of primary therapy is approximately 70%. Unfortunately for these women, once the disease recurs, treatment options are limited and the
disease is most likely incurable.
Alliance Partners in Therapeutic Areas
We currently have a number of collaborations around the development of our immunotherapy programs:
Intellectual Property
Patents and other intellectual property rights are crucial to our success. It is our policy to protect our intellectual property rights
through available means, including filing and prosecuting patent applications in the U.S. and other countries, protecting trade secrets, and utilizing regulatory protections such as data exclusivity. We also include restrictions regarding use and
disclosure of our proprietary information in our contracts with third parties, and utilize customary confidentiality agreements with our employees, consultants, clinical investigators and scientific advisors to protect our confidential information
and know-how. Together with our licensors, we also rely on trade secrets to protect our combined technology especially where we do not
S-5
believe patent protection is appropriate or obtainable. It is our policy to operate without infringing on, or misappropriating, the proprietary rights of others. The following chart summarizes
our intellectual property rights. The patents for the products are for the U.S. and certain foreign countries:
|
|
|
|
|
|
|
Drug Candidate
|
|
Indication
|
|
Scope
|
|
Estimated
Exclusivity
Period
|
GALE-401 (Anagrelide Controlled Release)
|
|
Platelet Lowering
|
|
Pending and/or issued
|
|
2029
|
NeuVax (nelipepimut-S)
|
|
Breast cancer recurrence
|
|
Pending and/or issued
|
|
2028
|
NeuVax (nelipepimut-S)
|
|
Gastric
|
|
Pending and/or issued
|
|
2028
|
NeuVax (nelipepimut-S)
|
|
DCIS
|
|
Pending and/or issued
|
|
2028
|
NeuVax in combination with trastuzumab
|
|
Breast cancer
|
|
Pending and/or issued
|
|
2026
|
NeuVax in combination with other compounds
|
|
Breast cancer
|
|
Pending and/or issued
|
|
2037
|
GALE-301 & GALE-302
|
|
Breast, ovarian and
endometrial cancer
|
|
Pending and/or issued
|
|
2036
|
Out-License Agreements
Teva Pharmaceuticals
Effective December 3, 2012, we entered into a license and supply agreement with ABIC Marketing Limited, a subsidiary of Teva
Pharmaceuticals (ABIC). Under the agreement, we granted ABIC exclusive rights to seek marketing approval in Israel for our NeuVax product candidate for the treatment of breast cancer following its approval by the FDA or the European
Medicines Agency, and to market, sell and distribute NeuVax in Israel assuming such approval is obtained. ABICs rights also include a right of first refusal in Israel for all future indications for which NeuVax may be approved.
Under the license and supply agreement, ABIC will assume responsibility for regulatory registration of NeuVax in Israel, provide financial
support for local development, and commercialize the product in the region in exchange for making royalty payments to us based on future sales of NeuVax. ABIC also agrees in the license and supply agreement to purchase all supplies of NeuVax from us
at a price determined according to a specified formula.
Dr. Reddys Laboratories Ltd.
Effective January 14, 2014, we entered into a strategic development and commercialization partnership with Dr. Reddys
Laboratories Ltd. (Dr. Reddys), under which we licensed commercial rights in India to Dr. Reddys for NeuVax in breast and gastric cancers and granted the right for Dr. Reddys Laboratories to conduct a Phase 2
investigational study in gastric cancer in India.
Kwangdong Pharmaceutical Co., Ltd.
Effective April 30, 2009, we entered into a license agreement with Kwangdong Pharmaceutical Co, Ltd (Kwangdong). Under the agreement, we
granted Kwangdong exclusive rights to seek marketing approval in The Republic of Korea (South Korea) for our NeuVax product candidate for the treatment of breast cancer following its approval by the FDA or the European Medicines Agency, and to
market, sell and distribute NeuVax in South Korea assuming such approval is obtained.
S-6
Recent Developments (in reverse chronological order)
Amendment to our purchase agreement with Lincoln Park Capital Fund, LLC
On February 6, 2017, the Company and Lincoln Park Capital Fund, LLC (Lincoln Park) amended the Purchase Agreement, as
amended, to decrease the value of Common Stock that the Company may sell to Lincoln Park from $55,000,000 to $15,600,000, a reduction of $39,400,000.
Positive Outcome from the Data Safety Monitoring Board on the Two NeuVax (nelipepimut-S) Clinical Trials in Combination with
Trastuzumab
On February 6, 2017, Galena reported the results from a meeting of the Data Safety Monitoring
Board (DSMB) for the two investigator-sponsored (IST) combination clinical trials with NeuVax (nelipepimut-S) plus trastuzumab. The DSMB reported that there are no safety concerns with either trial and neither was found to be futile.
For the Phase 2b trial in patients with low-to-intermediate HER2 expression (HER2 1+/2+), n=242 patients were evaluated, and the recommendation from the DSMB is to continue the trial with one revision to the statistical analysis plan regarding the
timing of the pre-specified interim analysis. Given the lengthy duration of enrollment for the trial, the DSMB determined that the pre-specified interim efficacy analysis be moved up from 12 months to 6 months after the last patient is enrolled.
Completion of enrollment is expected in the second quarter of 2017; therefore, the DSMB expects to perform the interim efficacy analysis near the end of 2017. For the Phase 2 trial in high-risk, HER2 3+ patients, and per the trial protocol, the
pre-specified interim safety analysis was also completed on n=50 patients and demonstrated that the agent is well tolerated with no increased cardiotoxicity associated with giving NeuVax in combination with trastuzumab. These findings were
similar to the findings presented in October 2016 from the HER2 1+/2+ trial. The recommendation from the DSMB is to continue the HER2 3+ trial unmodified.
Resignation of President and Chief Executive Officer
On January 31, 2017, Mark W. Schwartz, Ph.D., resigned from his position as President and Chief Executive Officer and as a member of the
board of directors of each of Galena Biopharma, Inc., Apthera, Inc. and Mills Pharmaceutical, LLC. For purposes of Dr. Schwartz Employment Agreement, dated as of August 21, 2014, Dr. Schwartz resignation was without
Good Reason. In connection with his resignation, on January 31, 2017, the Company executed a Separation Agreement and General Release with Dr. Schwartz and terminated Dr. Schwartzs Employment Agreement effective as
of the resignation date. The Separation Agreement will be filed with the Annual Report on Form 10-K for the year ending December 31, 2016. The Separation Agreement provides, among other things, for the following: (a) Dr. Schwartz
shall, within three days of January 31, 2017, receive his final paycheck and any unpaid vacation; (b) Dr. Schwartz shall receive $302,068.86 less required tax withholdings and authorized deductions, which is equal to six
(6) months of the Employees final base salary and six (6) months of the cost for continued health benefits coverage under COBRA; (c) in accordance with the Companys By-Laws and Certificate of Incorporation as well as
Delaware law, the Company shall indemnify and hold Dr. Schwartz harmless from any claims arising out of his actions as an employee and/or director of the Company; and (d) Dr. Schwartz agrees to release and waive all claims (both known
or unknown) that he may have against the Company as of the date of his resignation.
Evaluation of Strategic
Alternatives
On January 31, 2017, the Board of Directors announced that it is in the process of engaging an
outside advisor to evaluate strategic alternatives for the company focused on maximizing stockholder value. Potential strategic alternatives that may be explored or evaluated as part of this review include continuing to advance the clinical programs
as a stand-alone entity, a sale of the company, a business combination, merger or reverse merger, and a license or other disposition of corporate assets of the company. There is no set timetable for this process and there can be no assurance that
this process will result in a transaction. While the Company evaluates its strategic alternatives, Galenas investigator-sponsored immunotherapy trials will remain ongoing. The Company is evaluating the appropriate time to commence the GALE-401
trial and anticipates making a definitive determination in the second half of 2017.
S-7
FDA Confirms 505(b)(2) regulatory pathway for GALE-401 Phase 3
Trial
On December 28, 2016, Galena announced that after a productive meeting with the U.S. Food and Drug
Administration (FDA), the Agency confirmed that the GALE-401 development program is appropriate for a New Drug Application (NDA) filing using the 505(b)(2) regulatory pathway in patients who are intolerant to or failed to achieve an optimal response
with hydroxyurea.
Settlement with the Securities and Exchange Commission
On December 22, 2016, Galena Biopharma, Inc. (Galena) and its former Chief Executive Officer (CEO) reached an agreement in principle to a
proposed settlement that would resolve an investigation by the staff of the Securities and Exchange Commission (SEC) involving conduct in the period 2012-2014 regarding the commissioning of internet publications by outside promotional firms. Under
the terms of the proposed settlement framework, Galena and the former CEO would consent to the entry of an administrative order requiring that we and the former CEO cease and desist from any future violations of Sections 5(a), 5(b), 5(c), 17(a), and
17(b) of the Securities Act of 1933, as amended, and Section 10(b), 13(a), and 13(b)(2)(A) of the Securities Exchange Act of 1934, as amended, and various rules thereunder, without admitting or denying the findings in the order. Based upon the
proposed settlement framework, the Company will make a $200,000 penalty payment. In addition to other remedies, the proposed settlement framework would require the former CEO to make a disgorgement and prejudgment interest payment as well as a
penalty payment to the Commission. To address the issues raised by the SEC staffs investigation, in addition to previous governance enhancements we have implemented, we have voluntarily undertaken to implement a number of remedial actions
relating to securities offerings and our interactions with investor relations and public relations firms. The proposed settlement is subject to approval by the Commission and would acknowledge our cooperation in the investigation and confirm our
voluntary undertaking to continue that cooperation. If the Commission does not approve the settlement, we may need to enter into further discussions with the SEC staff to resolve the investigated matters on different terms and conditions. As a
result, there can be no assurance as to the final terms of any resolution including its financial impact or any future adjustment to the financial statements. A special committee of the board of directors has determined in response to an
indemnification claim by the former CEO that we are required under Delaware law to indemnify our former CEO for the disgorgement and prejudgment interest payment of approximately $750,000 that he would be required to pay if and when the settlement
is approved by the Commission. Any penalty payment that the former CEO will be required to make in connection with this matter ($600,000 under the proposed settlement framework) will be the responsibility of the former CEO.
Announced the Phase 2 Clinical Trial of NeuVax in DCIS is Open for Enrollment and Screening Patients
On December 14, 2016, the Company announced the NeuVax (nelipepimut-S) Phase 2 clinical trial entitled VADIS: Phase 2 trial of the
Nelipepimut-S Peptide
VA
ccine in Women with
D
C
IS
of the Breast is now open for enrollment and screening patients. The trial is being run in collaboration with the National Cancer Institute (NCI) and The University of Texas MD
Anderson Cancer Center Phase I and II Chemoprevention Consortium.
Presented Two Posters at the San Antonio Breast Cancer
Symposium
On December 12, 2016, the Company announced that two posters were presented at the San Antonio Breast Cancer
Symposium (SABCS). The poster, entitled, VADIS trial: Phase 2 trial of the nelipepimut-S peptide
va
ccine in women with
D
C
IS
of the breast, presented the trial design for the planned, Phase 2
investigator-sponsored clinical trial with NeuVax (nelipepimut-S) in patients with Ductal Carcinoma in Situ (DCIS). The poster, entitled, Determining the optimal vaccination strategy using a combination of the folate binding protein
(FBP) peptide vaccine (E39+GM-CSF) and an attenuated version (E39) to maximize the immunologic response in breast cancer patients, was presented on the breast cancer patients in the Companys GALE-301 (E39) and GALE-302 (E39)
Phase 1b clinical trial targeting Folate Binding Protein.
S-8
Presented GALE-301/GALE-302 Phase 1b Data
On November 14, 2016, data from Galenas GALE-301/GALE-302 clinical program was presented at the Society for Immunotherapy of Cancer
Conference 2016 in National Harbor, Maryland. The presentation, entitled, Phase Ib Trial of Two Folate Binding Protein (FBP) Peptide Booster Vaccines (E39 and E39) in Breast and Ovarian Cancer Patients, reported the
peptide-specific immune response to E39 and E39 after different combinations of vaccination and boosting. The data showed that both E39 and E39 are well tolerated with all related adverse events at grade 1 or grade 2. Though numbers were
small, patients boosted with the attenuated peptide showed increased CTL response to boosting regardless of significant residual immunity (SRI) resulting from the primary vaccination series (PVS). While this data needs to be confirmed with a larger
sample size, this is consistent with the theoretical advantage of boosting with an attenuated peptide, which is expected to induce less antigen-induced cell death of CTLs.
Appointment of Chief Financial Officer
On November 3, 2016, we announced that Stephen F. Ghiglieri joined the Company as Executive Vice President and Chief Financial Officer,
effective November 1, 2016. Mr. Ghiglieri, age 55, has served as the Chief Financial Officer since 2013 and Chief Operating Officer since 2015 at MedData, Inc. From 2003 until 2013, he served as Executive Vice President, Chief Operating
Officer and Chief Financial Officer of Neurogesx, Inc. Prior to that, he was Chief Financial Officer and Corporate Secretary at Hansen Medical, Inc. from 2002 to 2003; Executive Vice President, Chief Financial Officer and Corporate Secretary at
Avolent, Inc. from 2000 to 2002; Chief Financial Officer, Vice President Finance and Corporate Secretary at Andromedia, Inc. from 1999-2000; Vice President Finance and Administration, Chief Financial Officer and Corporate Secretary at Oacis
Healthcre Systems, Inc. from 1994 to 1999 and Controller at Oclassen Pharmaceuticals from 1992 to 1994. From 1984 to 1992, Mr. Ghiglieri was an Audit Manager at PricewaterhouseCoopers.
Announced a Reverse Stock Split
On October 31, 2016, we announced a reverse stock split of our shares of common stock at a ratio of 1-for-20 as approved by the Board of
Directors on October 26, 2016. The reverse stock split was authorized by the Companys stockholders at the Special Meeting of Stockholders held on October 21, 2016. The reverse stock split became effective on November 11, 2016
and the Companys common stock commenced trading on a split-adjusted basis on Wednesday, November 14, 2016 under the symbol GALE but under the new CUSIP number 363256504. Our consolidated financial statements for the year ended
December 31, 2015 and for the three, six and nine months ended March 31, 2016, June 30, 2016 and September 30, 2016, respectively, that are incorporated by reference into the prospectus supplement are presented without giving
effect to the reverse stock split. Unless otherwise stated, all shares and price per share numbers set forth in this prospectus supplement for periods prior to November 11, 2016 are presented after giving effect to the reverse stock split.
Presented GALE-301/GALE-302 Phase 1b Data
On October 20, 2016, Dr. Doreen Jackson delivered a podium presentation on Galenas GALE-301 and GALE-302 clinical program at
the American College of Surgeons Clinical Congress 2016. The Phase 1b is a single-center, randomized, single-blinded, three-arm study in patients with breast or ovarian cancer diagnosis who were treated with standard of care and were without
evidence of disease. This trial augments the Phase 1/2a trial with single-agent GALE-301 in ovarian and endometrial cancers. The presentation was entitled, A Phase Ib Trial Comparing Different Doses/Schedules of a Folate Binding Protein
(FBP)-derived Peptide Vaccine, E39, and its Attenuated Version, E39, to Induce Long-term FBP- specific Immunity in Disease-free Cancer Patients. In this trial, which enrolled mostly breast cancer patients, who have lower FBP exposure
than ovarian patients, the 500mcg dose appears to provide a more optimal immunological response. This differs from the results in ovarian cancer patients, who have much higher FBP expression, with potential secondary immune tolerance, where 1000mcg
was the optimal dose. However, E39 (GALE-302) given after E39 (GALE-301) was able to induce long-term immunity in both dosing cohorts, underscoring the potential importance of attenuated peptides in relatively antigen-naïve patients.
S-9
Presented NeuVax plus Trastuzumab Interim Safety Data
On October 10, 2016, we presented interim safety data from the NeuVax = Phase 2b combination study with trastuzumab at the European
Society for Medical Oncology (ESMO) 2016. The clinical trial is a randomized, multicenter, investigator-sponsored, 300 patient Phase 2b study enrolling HER2 1+ and 2+ node positive, and high-risk node negative patients. The poster, entitled ,
Interim safety analysis of a phase II trial combining trastuzumab and NeuVax, a HER2-targeted peptide vaccine, to prevent breast cancer recurrence in HER2 low expression, demonstrated that this novel combination of trastuzumab and NeuVax
in HER2 low-expressing (LE) patients is well-tolerated and the cardiac effects of trastuzumab are not impacted by the addition of NeuVax.
Recent
Operating Results and Financial Condition
Our cash and cash equivalents were approximately $18.1 million as of December 31,
2016. This amount is unaudited and preliminary, and does not present all information necessary for an understanding of our financial condition as of December 31, 2016. The review of our financial statements for the year ended December 31,
2016 is ongoing and could result in changes to this amount. Our financial statements for the year ended December 31, 2016 will not be available until after this offering is completed, and consequently will not be available to you prior to
investing in this offering.
In addition, under the terms of an amended debenture, we must maintain our restricted cash amount to the
lesser of $18.5 million and the outstanding balance of the amended debenture under certain conditions. As of December 31, 2016 our restricted cash balance reserved for the lender was $17.6 million. From the period of January 1, 2017 to
February 6, 2017 the holder of our amended debenture has redeemed an additional $3.95 million of outstanding principal related reducing the restricted cash balance to $13.7 million as of February 6, 2017.
We believe that our existing cash and cash equivalents together with the proceeds of this offering should be sufficient to fund our operations
for at least nine months. This projection is based on our current planned operations, wind down costs of the PRESENT Trial and further analysis of the data and causes of the failure of such clinical trial, anticipated payments for defense costs for
the cooperation and discussions with the staff in the SEC investigation and other governmental investigations, and resolution of the SEC investigation, and is subject to changes in our plans and uncertainties inherent in our business. We will need
to seek to replenish our existing cash and cash equivalents over the next nine months. We also have funding available under our amended purchase agreement with Lincoln Park Capital Fund, LLC and sales agreements with FBR and Maxim Group LLC
described in the previously filed prospectuses and other documents incorporated by reference into this prospectus supplement, but there is no guarantee that such funding will be available to us on favorable terms or will be sufficient to meet all of
our future funding needs. If we fail to obtain additional future funding when needed, we could be forced to scale back or terminate our operations, or to seek to merge with or to be acquired by another company. We may not be able to meet our
obligations as they come due, raising substantial doubts as to our ability to continue as a going concern. Any such inability to continue as a going concern may result in our common stock holders losing their entire investment. There is no guaranty
that we will become profitable or secure additional financing.
Corporate Information
Our principal executive offices are located at 2000 Crow Canyon Place, Suite 380, San Ramon, California 94583, and our phone number is
(855) 855-4253. Our website address is www.galenabiopharma.com. We do not incorporate the information on our website into this prospectus, and you should not consider such information part of this prospectus.
We were incorporated as Argonaut Pharmaceuticals, Inc. in Delaware on April 3, 2006 and changed our name to RXi Pharmaceuticals
Corporation on November 28, 2006. On September 26, 2011, we changed our company name from RXi Pharmaceuticals Corporation to Galena Biopharma, Inc.
S-10
The Offering
|
|
|
Common stock offered by us pursuant to this prospectus supplement
|
|
shares (excluding shares of common stock issuable upon exercise of the warrants being offered in this
offering). This prospectus supplement also relates to the offer and sale of the shares of common stock underlying the warrants being offered by us.
|
|
|
Warrants offered by us
|
|
Warrants to purchase up to shares of our common stock. Each warrant is exercisable to purchase of a share of
our common stock at an exercise price of $ per whole share. The warrants will be exercisable upon issuance and will expire on the five-year anniversary of issuance. See Description of Our
Securities.
|
|
|
Common stock to be outstanding after this offering
|
|
shares, or shares of our common stock assuming the warrants offered in this offering were to be immediately issued and exercised in
full.
|
|
|
Use of proceeds
|
|
We currently intend to use the net proceeds from this offering in our evaluation of strategic alternatives, to fund certain of our clinical trials of our product candidates, to augment our working capital and for general corporate
purposes. See Use of Proceeds on page
S-30
of this prospectus supplement for more information about our intended use of the net proceeds.
|
|
|
Dividend policy
|
|
We do not anticipate paying any cash dividends on our common stock.
|
|
|
The NASDAQ Capital Market symbol
|
|
Our common stock is listed on The NASDAQ Capital Market under the symbol GALE.
|
|
|
Risk factors
|
|
Investing in our securities involves significant risks. See Risk Factors beginning on page S-13 of this prospectus supplement and on page 1 of the accompanying prospectus and the documents incorporated by reference in
this prospectus supplement and the accompanying prospectus.
|
The number of shares of common stock shown above to be outstanding after this offering is based on 15,190,473
shares outstanding as of December 31, 2016 and excludes the following:
|
|
|
33,750 shares held in treasury;
|
|
|
|
560,924 shares of our common stock subject to outstanding options having a weighted-average exercise price of $41.40 per share;
|
|
|
|
500,691 shares of our common stock reserved for issuance in connection with future awards under our 2007 stock incentive plan;
|
|
|
|
20,929 shares of our common stock reserved for future sale under our employee stock purchase plan;
|
|
|
|
2,569,663 shares of our common stock subject to outstanding warrants having a weighted-average exercise price of $29.20 per share;
|
|
|
|
3,633,701 shares of our common stock issued in connection with redemption of outstanding principal and interest by the holder of our amended debenture from January 1, 2017 to February 7, 2017; and
|
|
|
|
shares of common stock issuable upon exercise of warrants to be issued in this offering.
|
S-11
The shares of common stock issuable upon the exercise of our outstanding warrants and the
exercise price of the warrants are subject to anti-dilution adjustments in certain circumstances. See Dilution for more information about these possible anti-dilution adjustments.
S-12
RISK FACTORS
Investing in our securities involves significant risks. Before making an investment decision, you should carefully consider the risks
described below, together with the information under Risk Factors in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and the other information incorporated by reference in this prospectus. Some of
these factors relate principally to our business and the industry in which we operate. Other factors relate principally to your investment in our common stock. If any of these risks were to occur, our business, financial condition, results of
operations, cash flows or prospects could be materially and adversely affected. In such case, you may lose all or part of your investment.
The risks and uncertainties described below and in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q
are not the only ones facing us. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also materially and adversely affect our business and operations.
Risks Relating to Our Former Commercial Operations
We are subject to U.S. federal and state health care fraud and abuse and false claims laws and regulations, and we recently have been subpoenaed in
connection with marketing and promotional practices related to Abstral. Prosecutions under such laws have increased in recent years and we may become subject to such prosecutions or related litigation under these laws. If we have not fully complied
with such laws, we could face substantial penalties.
Our former commercial operations and development programs are subject to
various U.S. federal and state fraud and abuse laws, including, without limitation, the federal False Claims Act, federal Anti-Kickback Statute, and the federal Sunshine Act. A federal investigation of two of the high-prescribing physicians for
Abstral has resulted in the criminal prosecution of the two physicians for alleged violations of the federal False Claims Act and other federal statutes. The criminal trial began on January 4, 2017. We have received a trial subpoena for
documents in connection with that investigation and we have been in contact with the U.S. Attorneys Office for the Southern District of Alabama, which is handling the criminal trial, and are cooperating in the production of documents. On
April 28, 2016, a second superseding indictment was filed in the criminal case, which added additional information about the defendant physicians and provided information regarding the facts and circumstances involving a rebate agreement
between the Company and the defendant physicians pharmacy as well as their ownership of our stock. Certain former employees have received trial subpoenas to appear at the trial and provide oral testimony. We have agreed to reimburse those
former employees attorneys fees. To our knowledge, we are not a target or subject of that investigation.
There also have been
federal and state investigations of a company that has a product that competes with Abstral in the same therapeutic class, and we have learned that the FDA and other governmental agencies are investigating our Abstral promotion practices. On
December 16, 2015, we received a subpoena issued by the U.S. Attorneys Office for the District of New Jersey requesting the production of a broad range of documents pertaining to our marketing and promotional practices for Abstral. We
have been in contact with the U.S. Attorneys Office for the District of New Jersey and are cooperating in the production of the requested documents. We have come to understand that the investigation being undertaken by the U.S. Attorneys
Office for the District of New Jersey and Department of Justice is a criminal investigation in addition to a civil investigation that could ultimately involve the company as well as one or more former employees. Pursuant to the Companys
charter, we are currently reimbursing certain former employees attorneys fees with respect to the investigation. We are cooperating with the civil and criminal investigation and through our outside counsel we have recently begun
preliminary discussions with the government aimed at the ultimate resolution of the investigation regarding the Company.
We may be
subject to legal or administrative actions as a result of these matters, or the impact of such matters. If we are found to be in violation of the False Claims Act, Anti-Kickback Statute, Patient Protection and Affordable Care Act, or any other
applicable state or any federal fraud and abuse laws, we may be subject to penalties, such as civil and criminal penalties, damages, fines, or an administrative action of exclusion from government health care reimbursement programs. We can make no
assurances as to the time or resources that will need to be devoted to these matters or their outcome, or the impact, if any, that these matters or any resulting legal or administrative proceedings may have on our business or financial condition.
We can make no assurances as to the time or resources that will need to be devoted to these matters or their outcome, or the impact, if
any, that these matters or any resulting legal or administrative proceedings may have on our business or financial condition.
Many of the
regulatory provisions that we are subject to include criminal provisions. If we are unable to comply with these provisions in the operation of our business we may become subject to civil and criminal investigations and proceedings that could have a
material adverse effect on our business, financial condition and prospects.
The federal False Claims Act prohibits persons from
knowingly filing, or causing to be filed, a false claim to, or the knowing use of false statements to obtain payment from, the federal government. Qui tam suits filed under the False Claims Act can be brought by any individual on behalf of the
government and such individuals, commonly known as relators or whistleblowers, may share in any amounts paid by the entity to the government in fines or settlement. The frequency of filing qui tam actions has increased
S-13
significantly in recent years, causing greater numbers of health care companies to have to defend such qui tam actions and pay substantial sums to settle such actions. The federal Anti-Kickback
Statute prohibits persons from knowingly and willfully soliciting, offering, receiving, or providing remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual, or the furnishing or arranging for a good
or service, for which payment may be made under a federal health care program such as the Medicare and Medicaid programs. Several courts have interpreted the statutes intent requirement to mean that if any one purpose of an arrangement
involving remuneration is to induce referrals of federal health care covered business, the statute has been violated. The Anti-Kickback Statute is broad, and despite a series of narrow safe harbors, prohibits many arrangements and practices that are
lawful in businesses outside of the health care industry. Penalties for violations of the federal Anti-Kickback Statute include criminal penalties and civil and administrative sanctions such as fines, imprisonment and possible exclusion from
Medicare, Medicaid and other federal health care programs. An alleged violation of the Anti- Kickback Statute may be used as a predicate offense to establish liability pursuant to other federal laws and regulations such as the federal False Claims
Act. Many states have also adopted laws similar to the federal Anti-Kickback Statute, some of which apply to the referral of patients for health care items or services reimbursed by any source, not only Medicare and Medicaid programs.
The federal Patient Protection and Affordable Care Act includes provisions expanding the ability of certain relators to bring actions that
would have been dismissed under prior law. When an entity is determined to have violated the federal False Claims Act, it may be required to pay up to three times the actual damages sustained by the government, plus civil penalties for each separate
false claim. The Deficit Reduction Act of 2005 encouraged states to enact or modify their state false claims acts to be at least as effective as the federal False Claims Act by granting states a portion of any federal Medicaid funds recovered
through Medicaid-related actions. Most states have enacted state false claims laws, and many of those states included laws including qui tam provisions. The federal Patient Protection and Affordable Care Act includes provisions known as the
Physician Payments Sunshine Act, which requires manufacturers of drugs, biologics, devices and medical supplies covered under Medicare and Medicaid to record any transfers of value to physicians and teaching hospitals and to report this data
beginning in 2013 to the Centers for Medicare and Medicaid Services for subsequent public disclosures. Manufacturers must also disclose investment interests held by physicians and their family members. Failure to submit the required information may
result in civil monetary penalties of up to $1 million per year for knowing violations and may result in liability under other federal laws or regulations. Similar reporting requirements have also been enacted on the state level in the U.S., and an
increasing number of countries worldwide either have adopted or are considering similar laws requiring transparency of interactions with health care professionals. In addition, some states such as Massachusetts and Vermont imposed an outright ban on
certain gifts to physicians. These laws could affect our product promotional activities by limiting the kinds of interactions we could have with hospitals, physicians or other potential purchasers or users of our system. Both the disclosure laws and
gift bans also will impose administrative, cost and compliance burdens on us.
We face product liability exposure and, if successful claims are
brought against us, we may incur substantial liability if our insurance coverage for those claims is inadequate.
The commercial
sale of our products after they are approved as well as the use of our products in clinical trials exposes us to possible product liability claims. This risk exists even if a product is approved for commercial sale by the FDA and manufactured in
facilities licensed and regulated by the FDA, if our products were sold to third parties, or if our products are provided in clinical trials. Our products are designed to affect important bodily functions and processes. Any side effects,
manufacturing defects, misuse or abuse associated with our products could result in injury to a patient or even death. For example, because the placebo may have performed better than NeuVax in the PRESENT Trial, the use of NeuVax may have worsened
the patients condition.
Product liability claims may be brought against us by consumers, health care providers, pharmaceutical
companies or others selling or otherwise coming into contact with our products or generic versions of our products. If we cannot successfully defend ourselves against product liability claims we could incur substantial liabilities. Because we have
sold Abstral and Zuplenz and provided NeuVax as a study drug in the Present Trial, regardless of merit or eventual outcome, product liability claims may result in:
|
|
|
impairment of our business reputation;
|
|
|
|
costs of related litigation;
|
|
|
|
distraction of managements attention from our primary business; or
|
|
|
|
substantial monetary awards to patients or other claimants.
|
We have obtained product
liability insurance coverage for commercial product sales with a $10 million per occurrence and a $10 million annual aggregate coverage limit. Our insurance coverage may not be sufficient to cover all of our product liability related expenses or
losses and may not cover us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive and, in the future, we may not be able to maintain insurance coverage at a reasonable cost, in sufficient amounts
or upon adequate terms to protect us against losses due to product liability. If we determine that it is prudent to increase our product liability coverage based on sales of our products, we may be unable to obtain this increased product liability
insurance on
S-14
commercially reasonable terms or at all. Large judgments have been awarded in class action or individual lawsuits based on drugs that had unanticipated side effects, including side effects that
may be less severe than those of our products. A successful product liability claim or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could decrease our cash and have a
material adverse effect on our business, results of operations, financial condition and prospects.
Our business involves the use of hazardous
materials and we and our third-party manufacturers and suppliers must comply with environmental laws and regulations, which can be expensive and restrict how we do business.
Our third-party manufacturers and suppliers activities involve the controlled storage, use and disposal of hazardous materials. We and our
manufacturers and suppliers are subject to laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials even after we sell or otherwise dispose of the products. In some cases, these hazardous
materials and various wastes resulting from their use will be stored at our contractors or manufacturers facilities pending use and disposal. We cannot completely eliminate the risk of contamination, which could cause injury to our employees
and others, environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. Although we expect that the safety
procedures utilized by our third-party contractors and manufacturers for handling and disposing of these materials will generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this will be the case or
eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources. We do not currently carry biological or hazardous waste
insurance coverage and our property and casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination.
We will continue to be responsible for certain liabilities and obligations related to Abstral and Zuplenz, and if unknown liabilities were to arise it
could have a material adverse effect on us.
Under our respective asset purchase agreements with Sentynl and Midatech, our future
obligations under our former agreements with Orexo AB and MonoSol have been assumed by Sentynl and Midatech, respectively, except that we will continue to be responsible for chargebacks, rebates, patient assistance and certain other product
distribution channel liabilities related to Abstral and Zuplenz for a specified period of time post-closing. We also will be responsible for any pre-closing liabilities and obligations related to Abstral and Zuplenz, including unknown liabilities,
and have agreed in the respective asset purchase agreements to indemnify Sentynl and Midatech for any breach of our representations, warranties and covenants in the respective asset purchase agreements up to a certain agreed to amount. We cannot
quantify these responsibilities to Sentynl and Midatech, but if substantial unknown liabilities were to arise, it could have a material adverse effect on our financial condition.
Risks Relating to Our Development Programs
Our
drug candidates may not receive regulatory approval or be successfully commercialized.
Before they can be marketed, our products
in development must be approved by the FDA or similar foreign governmental agencies. The process for obtaining FDA approval is both time-consuming and costly, with no certainty of a successful outcome. Before obtaining regulatory approval for the
sale of any drug candidate, we must conduct extensive preclinical tests and clinical trials to demonstrate the safety and efficacy in humans of our product candidates. Although our drug candidates have exhibited no serious adverse events
(SAEs) in the Phase 1 and 1/2 clinical trial, SAEs or other unexpected side effects may arising during further testing and development. A failure of any preclinical study or clinical trial can occur at any stage of testing. The results
of preclinical and initial clinical testing of these products may not necessarily indicate the results that will be obtained from later or more extensive testing. It also is possible to suffer significant setbacks in advanced clinical trials, even
after obtaining promising results in earlier trials.
Our Phase 3 PRESENT clinical trial has been stopped due to futility and though we have
conducted an investigation of the causes for the failure of the clinical trial, we are not certain that the investigation has identified the reason(s) for the failure.
On June 27, 2016, the Independent Data Monitoring Committee conducting the pre-planned interim analysis of the PRESENT Trial recommended
that we stop the clinical trial because of futility. We have conducted an investigation of the causes of the failure of the trial. As a result, our observations are that a phenomenon known as pseudoprogression likely had a meaningful impact on the
events assessed as NeuVax recurrences in the trial. The purpose of the NeuVax vaccine is to generate a HER2 directed T cell-based immune response targeting those undetected micro metastases and eradicate them before they grow into a clinically
detectable tumor. Pseudoprogression is a phenomenon that occurs when radiographic scans in patients responding to treatment with immunotherapy gives the appearance of progression due to increased tumor size or swelling from tumor-infiltrating
lymphocytes, or TILs, and other immune cells. In simple terms, the cancer looks like it has progressed on radiographic images, but in reality, the immunotherapy has done its job to create an immune response via inflammation around a micrometastasis.
Therefore, a growing tumor or a new tumor detected via imaging isnt always progressing cancer. The image of a new tumor may simply represent an immune system response to an undetectable micrometastasis that would not otherwise be seen on the
scan. In fact, irRESIST, which stands for immune related Response Evaluation Criteria In Solid Tumors, was recently adapted for clinical trials in patients
S-15
with active disease to better to provide better assessment on the effect of immunotherapeutic agents. irRESIST requires later confirmatory scans before calling a tumor a true progression
and this new criteria has yet to be used in the adjuvant setting. Additionally, in the adjuvant setting where PRESENT took place, immunological therapies may require extended monitoring over time to evaluate their effectiveness in preventing
recurrence with clinical significance. Although the rate of recurrence is highest in the first 24 months, the recurrence can occur years later, indicating that, in these late recurring patients, a number of micrometastases stay dormant and
dont become clinically significant for many years. Although this has not been known previously to the field, pseudo-recurrence could explain this phenomenon in the adjuvant setting. First, we believe that the low rate of recurrences in the
control group arm resulted from an overall improvement in the standard of care. In addition, proactive imaging led to the discovery of lesions, some of which may not have had any clinical significance at the time of identification. Finally, the
inflammation caused by tumor infiltrating lymphocytes, TILs, within the micrometastases and more specifically the NeuVax-induced cytotoxic T-cells, made them visible on scans in the NeuVax group and not in the control group. We now believe that
causing this inflammation, which is a mechanism through which the immunotherapy can eradicate the micro metastases in a group of patients, may have identified lesions that may have never progressed to clinical tumor. Because patients were
discontinued from this study at the time were identified as having DFS event, we do not know if some of these patients who were diagnosed with a recurrence on the CT scan would have progressed cancer. In summary, though we are applying the knowledge
and observations to our other immunotherapy programs, we may not have identified the reason(s) for the failure of the clinical trial.
Our products,
GALE 301 and GALE 302 have the same mechanism of actions NeuVax and may not be a viable product to prevent the recurrence of ovarian cancer or other types of cancers.
GALE 301/302, which have a similar mechanism of action as NeuVax, may no longer be a viable product to prevent the recurrence of ovarian
cancer or other types of cancer, depending upon the reasons for the causes of the failure of NeuVax.
A number of different factors could prevent us
from obtaining regulatory approval or commercializing our product candidates on a timely basis, or at all.
We, the FDA or other
applicable regulatory authorities, an Independent Data Safety Monitoring Board or IDSMB governing our clinical trials, or an institutional review board, or IRB, which is an independent committee registered with and overseen
by the U.S. Department of Health and Human Services, or HHS, that functions to approve, monitor and review biomedical and behavioral research involving humans, may suspend clinical trials of a drug candidate at any time for various
reasons, including if we or it believe the subjects or patients participating in such trials are being exposed to unacceptable health risks. Among other reasons, adverse side effects of a drug candidate on subjects or patients in a clinical trial
could result in the FDA or other regulatory authorities suspending or terminating the trial and refusing to approve a particular drug candidate for any or all indications of use.
Clinical trials of a new drug candidate require the enrollment of a sufficient number of patients, including patients who are suffering from
the disease the drug candidate is intended to treat and who meet other eligibility criteria. Rates of patient enrollment are affected by many factors, and delays in patient enrollment can result in increased costs and longer development times than
we expect at present. Patients who are enrolled at the outset of this standard of care also may eventually choose for personal reasons not to participate in the study. We also compete for eligible patients with other breast cancer trials underway
from time to time, and we may experience delays in patient enrollment due to the dependency of other large trials underway in the same patient population.
Clinical trials also require the review and oversight of IRBs, which approve and continually review clinical investigations to protect the
rights and welfare of human subjects. An inability or delay in obtaining IRB approval could prevent or delay the initiation and completion of clinical trials, and the FDA may decide not to consider any data or information derived from a clinical
investigation not subject to initial and continuing IRB review and approval.
In addition, cancer vaccines are a relatively new form of
therapeutic treatment and a very limited number of such products have received regulatory approval. Therefore, the FDA or other regulatory authority may apply standards for approval of a new cancer vaccine that is different from past experience.
Numerous factors could affect the timing, cost or outcome of our drug development efforts, including the following:
|
|
|
difficulties or delays in enrolling patients in planned phase 3 clinical trial of GALE-401 (anagrelide controlled release) or other clinical trials in conformity with required protocols or projected timeline or in our
other NeuVax clinical trials;
|
|
|
|
conditions imposed on us by the FDA or comparable foreign authorities regarding the scope or design of our clinical trials;
|
S-16
|
|
|
difficulties or delays in arranging for third parties to conduct clinical trials of our product candidates;
|
|
|
|
problems in engaging IRBs to oversee trials or problems in obtaining or maintaining IRB approval of studies;
|
|
|
|
third-party contractors failing to comply with regulatory requirements or meet their contractual obligations to us in a timely manner;
|
|
|
|
our drug candidates having very different chemical and pharmacological properties in humans than in laboratory testing and interacting with human biological systems in unforeseen, ineffective or harmful ways, and the
possibility that our previous Phase 1 or Phase 2 trials will not be indicative of our drug candidates performance in larger patient populations;
|
|
|
|
the need to suspend or terminate our clinical trials if the participants are being exposed to unacceptable health risks;
|
|
|
|
insufficient or inadequate supply or quality of our drug candidates or other necessary materials necessary to conduct our clinical trials;
|
|
|
|
disruption at our foreign clinical trial sites resulting from local social or political unrest or other geopolitical factors;
|
|
|
|
effects of our drug candidates not being the desired effects or including undesirable side effects or the drug candidates having other unexpected characteristics;
|
|
|
|
negative or inconclusive results from our clinical trials or the clinical trials of others for drug candidates similar to our own or inability to generate statistically significant data confirming the efficacy of the
product being tested;
|
|
|
|
adverse results obtained by other companies developing similar drugs;
|
|
|
|
modification of the drug during testing;
|
|
|
|
our capital resources; and
|
|
|
|
reallocation of our financial and other resources to other clinical programs.
|
It is possible
that none of the product candidates that we develop will obtain the appropriate regulatory approvals necessary for us to begin selling them or that any regulatory approval to market a product may be subject to limitations on the indicated uses for
which we may market the product. The time required to obtain FDA and other approvals is unpredictable but often can take years following the commencement of clinical trials, depending upon the complexity of the drug candidate. Any analysis we
perform of data from clinical activities is subject to confirmation and interpretation by regulatory authorities, which could delay, limit or prevent regulatory approval. Any delay or failure in obtaining required approvals could have a material
adverse effect on our ability to generate revenue from the particular drug candidate.
In addition, the length of time to develop the
product candidates as well as any regulatory delays in the development and regulatory approval process could cause the patent exclusivity to be unavailable or greatly reduced for each product candidate. The lack of patent exclusivity could have a
material adverse effect on our ability to generate revenue from the particular drug candidate.
We are also subject to numerous foreign
regulatory requirements governing the conduct of clinical trials, manufacturing and marketing authorization, pricing and third-party reimbursement. The foreign regulatory approval process includes all of the risks associated with the FDA approval
described above as well as risks attributable to the satisfaction of local regulations in foreign jurisdictions. Approval by the FDA does not assure approval by regulatory authorities outside of the U.S.
S-17
We are dependent upon contract manufacturers for clinical supplies of our product candidates.
We do not have the facilities or expertise to manufacture supplies of any of our product candidates for clinical trials. Accordingly, we are
dependent upon contract manufacturers for these supplies. There can be no assurance that we will be able to secure needed supply arrangements on reasonable terms, or at all. Our failure to secure these arrangements as needed could have a materially
adverse effect on our ability to complete the development of our product candidates or, if we obtain regulatory approval for our product candidates, to commercialize them.
Our current plans call for the manufacture of our compounds by contract manufacturers offering research grade, Good Laboratory Practices grade
and Good Manufacturing Practices grade materials for preclinical studies (e.g., toxicology studies) and for clinical use. Certain of our product candidates are complex molecules requiring many synthesis steps, which may lead to challenges with
purification and scale-up. These challenges could result in increased costs and delays in manufacturing. For GALE-401, we will change contract manufacturers for the supply of the clinical study drug and the commercial product, which may lead to
delays in the initiation and completion of the Phase 3 trial and filing for regulatory approval.
NeuVax is administered in combination
with Leukine, a GM-CSF available in both liquid and lyopholyzed forms exclusively from Genzyme Corporation, or Genzyme, a subsidiary of Sanofi-Aventis. We will continue to be dependent on Genzyme for our supply of Leukine in
connection with the ongoing NeuVax and GALE-301/GALE-302 trials and the potential commercial manufacture of these programs. Any temporary interruptions or discontinuation of the availability of Leukine, or any determination by us to change the
GM-CSF used with NeuVax or GALE-301/GALE-302, may have a material adverse effect on our clinical trials and any commercialization of the assets.
We
may not be able to establish or maintain the third-party relationships that are necessary to develop or potentially commercialize some or all of our product candidates.
We expect to depend on collaborators, partners, licensees, clinical research organizations and other third parties to support our discovery
efforts, to formulate product candidates, to manufacture our product candidates, and to conduct clinical trials for some or all of our product candidates. We cannot guarantee that we will be able to successfully negotiate agreements for or maintain
relationships with collaborators, partners, licensees, clinical investigators, vendors and other third parties on favorable terms, if at all. Our ability to successfully negotiate such agreements will depend on, among other things, potential
partners evaluation of the superiority of our technology over competing technologies and the quality of the preclinical and clinical data that we have generated, and the perceived risks specific to developing our product candidates. If we are
unable to obtain or maintain these agreements, we may not be able to clinically develop, formulate, manufacture, obtain regulatory approvals for or commercialize our product candidates. Under certain license agreements that we have already entered
into, we have minimum dollar amounts per year that we are obligated to spend on the development of the technology we have licensed from our contract partners and other obligations to maintain certain licenses. If we fail to meet this requirement
under any of our licenses that contain such requirements or any other obligations under these licenses, we may be in breach of our obligations under such agreement, which may result in the loss of the technology licensed. We cannot necessarily
control the amount or timing of resources that our contract partners will devote to our research and development programs, product candidates or potential product candidates, and we cannot guarantee that these parties will fulfill its obligations to
us under these arrangements in a timely fashion. We may not be able to readily terminate any such agreements with contract partners even if such contract partners do not fulfill its obligations to us.
In addition, we may receive notices from third parties from time to time alleging that our technology or product candidates infringe upon the
intellectual property rights of those third parties. Any assertion by third parties that our activities or product candidates infringe upon its intellectual property rights may adversely affect our ability to secure strategic partners or licensees
for our technology or product candidates or our ability to secure or maintain manufacturers for our compounds.
S-18
We are subject to competition and may not be able to compete successfully.
The biotechnology industry, including the cancer immunotherapy market, is intensely competitive and involves a high degree of risk. We compete
with other companies that have far greater experience and financial, research and technical resources than us. Potential competitors in the U.S. and worldwide are numerous and include pharmaceutical and biotechnology companies, educational
institutions and research foundations, many of which have substantially greater capital resources, marketing experience, research and development staffs and facilities than us. Some of our competitors may develop and commercialize products that
compete directly with those incorporating our technology, introduce products to market earlier than our products or on a more cost effective basis. In addition, our technology may be subject to competition from other technology or methods developed
using techniques other than those developed by traditional biotechnology methods. Our competitors compete with us in recruiting and retaining qualified scientific and management personnel as well as in acquiring technologies complementary to our
technology. We and our collaborators may face competition with respect to product efficacy and safety, ease of use and adaptability to various modes of administration, acceptance by physicians, the timing and scope of regulatory approvals,
availability of resources, reimbursement coverage, price and patent position, including the potentially dominant patent positions of others. An inability to successfully complete our product development could lead to us having limited prospects for
establishing market share or generating revenue from our technology.
GALE-401 contains the active ingredient, anagrelide, a FDA-approved
product, for the treatment of patients with myeloproliferative neoplasms (MPNs) to lower abnormally elevated platelet levels. The currently available immediate release (IR) version of anagrelide causes adverse events that are believed to be dose and
plasma concentration dependent. These adverse events may limit the use of the IR version of the drug. Therefore, reducing the maximum concentration (Cmax) is hypothesized to reduce the side effects, but preserve efficacy, potentially allowing a
broader use of the drug. We have analyzed our data and the treatment landscape for MPNs, with a current focus on Essential Thrombocythemia (ET) where we see an unmet medical need in patients who are intolerant to the current standard of care. We may
be advancing GALE-401 into a pivotal trial. The risks include regulatory (agreement with regulatory agency on the development plan), operational (rate of enrollment), and statistical confirmation of the expected therapeutic efficacy. In addition,
there are other potential competitors whose clinical trials may be successful and obtain regulatory approval prior to our regulatory approval, if our pivotal trial is successful.
We are dependent on technologies we license, and if we lose the right to license such technologies or we fail to license new technologies in the future,
our ability to develop new products would be harmed.
We currently are dependent on licenses from third parties for technologies
relating to our product candidates. Our current licenses impose, and any future licenses we enter into are likely to impose, various development, funding, royalty, diligence, sublicensing, insurance and other obligations on us. If our license with
respect to any of these technologies is terminated for any reason, the development of the products contemplated by the licenses would be delayed, or suspended altogether, while we seek to license similar technology or develop new non-infringing
technology. The costs of obtaining new licenses are high.
Risks associated with operating in foreign countries could materially adversely affect
our product development.
We may conduct future studies in countries outside of the U.S. Consequently, we may be subject to risks
related to operating in foreign countries. Risks associated with conducting operations in foreign countries include:
|
|
|
differing regulatory requirements for drug approvals and regulation of approved drugs in foreign countries;
|
|
|
|
unexpected changes in tariffs, trade barriers and regulatory requirements; economic weakness, including inflation, or political instability in particular foreign economies and markets; compliance with tax, employment,
immigration and labor laws for employees living or traveling abroad; foreign taxes, including withholding of payroll taxes;
|
|
|
|
foreign currency fluctuations, which could result in increased operating expenses or reduced revenues, and other obligations incident to doing business or operating in another country;
|
|
|
|
workforce uncertainty in countries where labor unrest is more common than in the U.S.;
|
|
|
|
production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and
|
|
|
|
business interruptions resulting from geopolitical actions, including war and terrorism.
|
In
addition, there may be political instability, including war, terrorism, riots, civil insurrection or social unrest, and natural or man-made disasters, including famine, flood, fire, earthquake, storm or disease, which could seriously harm the
progress of our clinical trials at sites in particular foreign countries or regions.
S-19
Risks Relating to Our Financial Position and Capital Requirements
We may not be able to obtain sufficient financing, and may not be able to develop our product candidates.
We had cash and cash equivalents of approximately $24.5 million as of September 30, 2016. In addition, under the terms of an amended
debenture, we have approximately $18.5 million of restricted cash that is reserved for a lender who had the option to redeem all, or part, of such amount within 30 trading days of our public announcement on June 29, 2016, of the discontinuation
of the Phase 3 PRESENT Trial upon the IDMCs recommendation on June 27, 2016. We negotiated an amendment with the lender in part, that reduced the restricted cash amount to the lesser of $18.5 million or the outstanding balance of the
amended debenture under certain conditions. We had no revenue for the quarter ending September 30, 2016, and our cash burn from operations for the quarter ending September 30, 2016 was approximately $12.2 million. We believe that our
existing cash and cash equivalents should be sufficient to fund our operations for at least six months. This projection is based on our current limited planned operations, wind down costs of the PRESENT Trial, anticipated payments for defense costs
for the other governmental investigations, and resolution of the SEC investigation and governmental investigations, and is subject to changes in our plans and uncertainties inherent in our business. We will need to seek to replenish our existing
cash and cash equivalents over the next six months. We also have funding available under our amended purchase agreement with Lincoln Park Capital Fund, LLC and sales agreements with FBR and Maxim Group LLC described in the previously filed
prospectuses and other documents incorporated by reference into this prospectus supplement, but there is no guarantee that such funding will be available to us on favorable terms or will be sufficient to meet all of our future funding needs. At our
annual meeting of stockholders adjourned on July 15, 2016, our stockholders approved an increase in our authorized common stock from 275,000,000 to 350,000,000. In addition, our shareholders authorized the Board to approve a reverse stock split
within twelve months of October 21, 2016 at a ratio within 1:2 and 1:20. There was no reduction in the amount of authorized shares. The Board approved a reverse stock split at a ratio of 1:20 to be effective November 11, 2016, we are not
able to predict whether volume of shares post reverse stock split will be sufficient based upon the reverse stock split price to meet the Companys ongoing financing requirements to maintain the Companys operations. If we fail to obtain
additional future funding when needed, we could be forced to scale back or terminate our operations, or to seek to merge with or to be acquired by another company. We may not be able to meet our obligations as they come due, raising substantial
doubts as to our ability to continue as a going concern. Any such inability to continue as a going concern may result in our common stock holders losing their entire investment. There is no guaranty that we will become profitable or secure
additional financing.
If we fail to obtain additional future funding when needed, we could be forced to scale back or terminate our
operations, or to seek to merge with or to be acquired by another company. We may not be able to meet our obligations as they come due, raising substantial doubts as to our ability to continue as a going concern. Any such inability to continue as a
going concern may result in our common stock holders losing their entire investment. There is no guaranty that we will become profitable or secure additional financing.
We expect to continue to incur significant research and development expenses, which may make it difficult for us to attain profitability, and may lead
to uncertainty about our ability to continue as a going concern.
Substantial funds were expended to develop our technologies and
product candidates, and additional substantial funds will be required for further preclinical testing and clinical trials of our product candidates, and to manufacture and market any products that are approved for commercial sale. Because the
successful development of our products is uncertain, we are unable to precisely estimate the actual funds we will require to develop and potentially commercialize them. In addition, we may not be able to generate enough revenue, even if we are able
to commercialize any of our product candidates, to become profitable.
In the event that we are unable to achieve or sustain profitability
or to secure additional financing, we may not be able to meet our obligations as they come due, raising substantial doubts as to our ability to continue as a going concern. Any such inability to continue as a going concern may result in our common
stock holders losing their entire investment. There is no guaranty that we will become profitable or secure additional financing. Our financial statements contemplate that we will continue as a going concern and do not contain any adjustments that
might result if we were unable to continue as a going concern. Changes in our operating plans, our existing and anticipated working capital needs, the acceleration or modification of our expansion plans, increased expenses, potential acquisitions or
other events will all affect our ability to continue as a going concern. Future financing may be obtained through, and future development efforts may be paid for by, the issuance of debt or equity, which may have an adverse effect on our security
holders or may otherwise adversely affect our business.
If we raise funds through the issuance of debt or equity, any debt securities or
preferred stock issued will have rights, preferences and privileges senior to those of holders of our common stock in the event of a liquidation. In such event, there is a possibility that once all senior claims are settled, there may be no assets
remaining to pay out to the holders of common stock. In addition, if we raise funds through the issuance of additional equity, whether through private placements or additional public offerings, such an issuance would dilute your ownership in us.
S-20
The terms of debt securities may also impose restrictions on our operations, which may include
limiting our ability to incur additional indebtedness, to pay dividends on or repurchase our capital stock, or to make certain acquisitions or investments. In addition, we may be subject to covenants requiring us to satisfy certain financial tests
and ratios, and our ability to satisfy such covenants may be affected by events outside of our control.
You may have difficulty evaluating our
business, and our historical financial information may not be representative of our future results.
We have closed our PRESENT
Trial for futility, are evaluating the appropriate time to commence the GALE-401 trial and anticipate making a definitive determination in the second half of 2017, and plan to continue to support the investigator-sponsored immunotherapy trials. As a
result, we will have no recurring revenues unless and until we are able to obtain marketing approval of one or more of our other product candidates and our historical financial information may not be representative of our future results.
We may be unable to comply with our reporting and other requirements under federal securities laws.
As a publicly traded company, we are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, or the
Exchange Act, and the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act. In addition, the Exchange Act requires that we file annual, quarterly and current reports. Our failure to prepare and disclose this information in a
timely manner could subject us to penalties under federal securities laws, expose us to lawsuits and restrict our ability to access financing. The Sarbanes-Oxley Act requires that we, among other things, establish and maintain effective internal
controls and procedures for financial reporting. From time to time we evaluate our existing internal controls in light of the standards adopted by the Public Company Accounting Oversight Board. It is possible that we or our independent registered
public accounting firm may identify significant deficiencies or material weaknesses in our internal control over financial reporting in the future. Any failure or difficulties in implementing and maintaining these controls could cause us to fail to
meet the periodic reporting obligations or result in material misstatements in our financial statements.
Section 404 of the
Sarbanes-Oxley Act requires annual management and independent auditor assessments of the effectiveness of our internal control over financial reporting. Our failure to satisfy the requirements of Section 404 on a timely basis could result in
the loss of investor confidence in the reliability of our financial statements, which in turn could have a material adverse effect on our business and our common stock.
Risks Related to Our Intellectual Property
We may
not be able to obtain and enforce patent rights or other intellectual property rights that cover our product candidates and that are of sufficient breadth to prevent third parties from competing against us.
Our success with respect to our product candidates will depend in part on our ability to obtain and maintain patent protection in the U.S. and
abroad, to preserve our trade secrets, and to prevent third parties from infringing upon our proprietary rights. Our patents and patent applications, however, may not be sufficient to provide protection for NeuVax or our other products and product
candidates against commercial competition.
The active peptide found in NeuVax, the E75 peptide, has been known and studied for many
years. We have one issued U.S. patent, US 6,514,942, covering the composition of matter of the E75 peptide, which expired in mid-2015, prior to any potential commercialization of NeuVax. We do not have and will not be able to obtain any composition
of matter patent protection for E75, the active peptide in NeuVax. We also have a license from The Henry M. Jackson Foundation to issued U.S., European, Japanese, Korean, Mexican and Australian method of use patents, which expire in 2028, that are
directed to a method of inducing immunity against breast cancer recurrence by administering a composition comprising the E75 peptide to patients who have both an immunohistochemistry (IHC) rating of 1+ or 2+ for HER2/neu protein expression, as well
as a fluorescence in situ hybridization (FISH) rating of less than about 2.0 for HER2/neu gene expression. The license further includes issued U.S., Japanese & Australian method of use patents directed to a method of inducing immunity against
recurrence of any HER2/neu expressing tumors by administering the E75 peptide to patients with tumors having a FISH rating of less than about 2.0 for HER2/neu gene expression; an issued U.S. patent which includes claims to the use of E75 to reduce
the risk of cancer recurrence, including bone only recurrence; and pending applications with similar claims in a number of foreign jurisdiction, all of which expire in 2028. Also included in the license is an issued U.S. method of use patent, which
expires in 2026, that is directed to the use of NeuVax in combination with Herceptin® to treat any HER2/neu expressing cancer. Thus, our method of use patents may not prevent competitors from seeking to develop and market NeuVax for use in
cancer patients who do not meet these criteria. If any such alternative uses were approved, this could lead to off-label use and price erosion for our NeuVax product. We may seek FDA approval for use of NeuVax to treat cancer patients who fall
outside the claimed IHC and FISH ranges and for other cancers as well. Although we are pursuing additional patent protection for NeuVax through pending patent applications, we may not be able to obtain additional patent protection that would provide
us with a significant commercial advantage.
S-21
Anagrelide hydrochloride, the sole active pharmaceutical ingredient, or API, in
GALE-401, has been approved for many years and, thus, it is not possible to obtain composition of matter patents that cover anagrelide hydrochloride. As a result, competitors who obtain the requisite regulatory approval can offer products with the
same API as GALE-401, so long as the competitors do not infringe any formulation patents that we may have or may obtain or license, if any. The only patent protection that we have or are likely to obtain covering GALE-401 are patents relating to
specific formulations, methods using these formulations, and methods of manufacturing and packaging. We have an issued U.S. Patent, which expires in 2020, covering methods of using anagrelide to reduce platelet count in patients subject to
veno-occlusive events. We have granted patents in the U.S., United Kingdom and Japan, which expire in 2029, covering controlled release formulations of anagrelide and methods of use. We also are prosecuting pending patent applications in other
territories including, but not limited to, the U.S. Europe, India and Japan, which may not issue prior to any potential commercialization of GALE-401. We may seek FDA approval for use of GALE-401 to treat patients with myeloproliferative neoplasms
that include several hematological disorders. Although we are pursuing additional patent protection for GALE-401 through pending patent applications, we may not be able to obtain additional patent protection that would provide us with a significant
commercial advantage.
The active peptides found in GALE-301 and GALE-302 are derived from Folate Binding Protein. One of the active
peptides, E39, has been known and studied for many years. The other active peptide, GALE-302, is a derivative of E39. We have a license from The Henry M. Jackson Foundation to issued and granted patents in the U.S., Europe, Canada, and Japan,
covering composition of matter for the E39 derivative peptides, including GALE-302, alone and in combination with E39, as well as the use of these compositions for the treatment of cancer. These patents are expected to expire in 2022, prior to any
potential commercialization of GALE-301. In addition, we have pending U.S. and International (PCT) applications directed to specific dosage regimens of GALE-301 and GALE-302 combinations. Any patents which issue based on these applications would be
expected to expire in 2036, absent any patent term adjustment. We do not have and will not be able to obtain any composition of matter patent protection for the E39 peptide in any territory. The license we have from The Henry M. Jackson Foundation
grants us the right to develop and market GALE-301 for any use, including methods of treating cancer, our patents may not prevent competitors from seeking to develop and market the E39 peptide alone. If any such alternative uses of compositions
containing the E39 peptide were approved, this could lead to off label use and price erosion for GALE-301. We may seek FDA approval for use of GALE-301, alone or in combination with GALE-302, to treat cancer patients with ovarian and endometrial
cancers and for other cancers, as well. Although we are pursuing additional patent protection for GALE-301 and the combination of GALE-301 and GALE-302 through pending patent applications, we may not be able to obtain additional patent protection
that would provide us with a significant commercial advantage.
Our ability to obtain, maintain and enforce patents is uncertain and
involves complex legal and factual questions. Accordingly, rights under any patents we have or may obtain or license may not provide us with sufficient protection for our commercial product and product candidates to afford a commercial advantage
against competitive products or processes, including those from branded and generic pharmaceutical companies. In addition, we cannot guarantee that any patents will issue from any pending or future patent applications owned by or licensed to us. Nor
can we guarantee that the claims of these patents will be held valid or enforceable by the courts or will provide us with any significant protection against competitive products or otherwise be commercially valuable to us.
Changes in either the patent laws or in the interpretations of patent laws in the U.S. or abroad may diminish the value of our intellectual
property. In addition, on September 16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to the U.S. patent law. These include provisions that
affect the way patent applications will be prosecuted and may also affect patent litigation. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act, in
particular the first-to-file provision and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement of or defense of our issued patents, all of which could have a
material adverse effect on our business and financial condition. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents.
While we intend to take actions reasonably necessary to enforce our patent rights, we may not be able to detect infringement of our own or
in-licensed patents, which may be especially difficult for methods of manufacturing or formulation products, and we depend, in part, on our licensors and collaborators to protect a substantial portion of our proprietary rights. In addition, third
parties may challenge our in-licensed patents and any of our own patents that we may obtain, which could result in the invalidation or unenforceability of some or all of the relevant patent claims. Litigation or other proceedings to enforce or
defend intellectual property rights is very complex, expensive, and may divert our managements attention from our core business and may result in unfavorable results that could adversely affect our ability to prevent third parties from
competing with us.
If another party has reason to assert a substantial new question of patentability against any of our claims in our own
and in-licensed patents, the third party can request that the patent claims be reexamined, which may result in a loss of scope of some claims or a loss of the entire patent. In addition to potential infringement suits and, interference and
reexamination proceedings, we may become a party to patent opposition proceedings where either the patentability of the inventions subject of our patents are challenged, or we are challenging the patents of others. The costs of these proceedings
could be substantial, and it is possible that such efforts would be unsuccessful. As the medical device, biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that others may assert our commercial product
and/or product candidates infringe their patent rights. If a third-partys
S-22
patents were found to cover our commercial product and product candidates, proprietary technologies or its uses, we or our collaborators could be enjoined by a court and required to pay damages
and could be unable to continue to commercialize our products or use our proprietary technologies unless we or it obtained a license to the patent. A license may not be available to us or our collaborators on acceptable terms, if at all. In
addition, during litigation, the patent holder could obtain a preliminary injunction or other equitable relief, which could prohibit us from making, using or selling our commercial product and product candidates pending a trial on the merits, which
could be years away.
Proprietary trade secrets and unpatented know-how are also very important to our business. Although we have taken
steps to protect our trade secrets and unpatented know-how, by entering into confidentiality agreements with third parties, and proprietary information and invention agreements with certain employees, consultants and advisors, third parties may
still obtain this information or we may be unable to protect our rights. We also have limited control over the protection of trade secrets used by our licensors, collaborators and suppliers. There can be no assurance that binding agreements will not
be breached, that we would have adequate remedies for any breach, or that our trade secrets and unpatented know-how will not otherwise become known or be independently discovered by our competitors. If trade secrets are independently discovered, we
would not be able to prevent their use. Enforcing a claim that a third party illegally obtained and is using our trade secrets or unpatented know-how is expensive and time consuming, and the outcome is unpredictable.
We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed to us alleged trade
secrets of their other clients or former employers. As is common in the biotechnology and pharmaceutical industry, certain of our employees were formerly employed by other biotechnology or pharmaceutical companies, including our competitors or
potential competitors. Moreover, we engage the services of consultants to assist us in the development of our commercial product and product candidates, many of whom were previously employed at or may have previously been or are currently providing
consulting services to, other biotechnology or pharmaceutical companies, including our competitors or potential competitors. We may be subject to claims that these employees and consultants or we have inadvertently or otherwise used or disclosed
trade secrets or other proprietary information of their former employers or their former or current customers. Litigation may be necessary to defend against these types of claims. Even if we are successful in defending against any such claims, any
such litigation would likely be protracted, expensive, a distraction to our management team, not viewed favorably by investors and other third parties, and may potentially result in an unfavorable outcome.
Our product candidates may face competition sooner than expected after the expiration of our composition of matter patent protection for such products.
Our composition of matter patents for many of our product candidates have expired or will expire prior to any product approval.
We intend to seek data exclusivity or market exclusivity for our NeuVax as well as our GALE-301 and GALE-302 product candidates provided under the Federal Food, Drug and Cosmetic Act, or FDCA, and similar laws in other countries. We believe that
these product candidates will qualify for 12 years of data exclusivity under the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which was enacted as part of the Patient Protection and Affordable Care Act and the Health Care and
Education Affordability Reconciliation Act of 2010 (collectively, the Affordable Care Act or ACA) enacted in March 2010. Under the BPCIA, an application for a biosimilar product or biologics license application (BLA) cannot be submitted to the FDA
until four years, or if approved by the FDA, until 12 years, after the original brand product identified as the reference product is approved under a BLA. The BPCIA provides an abbreviated pathway for the approval of biosimilar and interchangeable
biological products. The new abbreviated regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as interchangeable based on its similarity
to an existing brand product. The new law is complex and is only beginning to be interpreted and implemented by the FDA. While it is uncertain when any such processes may be fully adopted by the FDA, any such processes could have a material adverse
effect on the future commercial prospects for our biological product candidates. There is also a risk that the U.S. Congress could amend the BPCIA to shorten this exclusivity period as proposed by President Obama, potentially creating the
opportunity for biosimilar competition sooner than anticipated after the expiration of our patent protection. Moreover, the extent to which a biosimilar, once approved, will be substituted for any reference product in a way that is similar to
traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.
If our product candidates are not considered biologics that would qualify for exclusivity under the BPCIA, they may be eligible for market
exclusivity as drugs under the FDCA. The FDCA provides a five-year period of non-patent marketing exclusivity within the U.S. to the first applicant to gain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has
not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an abbreviated new drug
application, or ANDA, or a 505(b)(2) NDA, submitted by another company for another version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be
submitted after four years if it contains a certification of patent invalidity or non-infringement. The FDCA also provides three years of marketing exclusivity for an NDA, 505(b)(2) NDA or supplement to an existing NDA if new clinical
investigations, other than bioavailability studies, that were
S-23
conducted or sponsored by the applicant are deemed by FDA to be essential to the approval of the application, for example, for new indications, dosages, or strengths of an existing drug. This
three-year exclusivity covers only the conditions associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the original active agent.
Even if, as we expect, GALE-301 and GALE-302 are considered to be reference products eligible for 12 years of exclusivity under the BPCIA or
five years of exclusivity under the FDCA, another company could market competing products if the FDA approves a full BLA or full NDA for such product containing the sponsors own preclinical data and data from adequate and well-controlled
clinical trials to demonstrate the safety, purity and potency of the products.
In some countries outside of the U.S., peptide vaccines,
such as GALE-301 and GALE-302, are regulated as chemical drugs rather than as biologics and may or may not be eligible for non-patent exclusivity.
Although we have received orphan drug designation for both GALE-301, as well as GALE-301and GALE-302, there is no guarantee that the drugs
will be successfully approved by the FDA, that they will be commercially successful in the marketplace, or that another drug will not be approved for the same indication ahead of our drugs.
Risks Relating to Ownership of Our Common Stock
If our common stock trade prices less than $1.00, our common stock may be subject to delisting from the NASDAQ Capital Market, which is
the minimum bid price requirement under NASDAQs continued listing standards.
The continued listing requirements of the
NASDAQ Capital Market require that the closing bid price of our common stock not be less than $1.00. On February 6, 2017 the last reported sale price of our common stock on The NASDAQ Capital Market was $1.41 per share. On January 18,
2017, we received an inquiry from NASDAQ Listing Qualifications Department seeking information in connection with the subpoenas issued to the Company by the US Attorneys Office for the District of New Jersey and the U.S. Attorneys Office
for the Southern District of Alabama. We have responded to the inquiry on February 1, 2017. If we are not in compliance with the listing requirements under NASDAQ Listing Rule 5502(a)(2), we could be delisted by NASDAQ.
If our trading price falls below $1.00 for 30 trading days or more, we may receive a notice from NASDAQ informing us that we may be delisted
unless our trading price is above $1.00 for more than 10 trading days. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we would have 180 calendar days to regain compliance with the $1.00 minimum bid price requirement. We can regain compliance
with the $1.00 minimum bid listing requirement if the closing bid price is at least $1.00 per share for a minimum of ten consecutive trading days during this initial 180-day compliance period. If compliance is not achieved within the 180-day period,
NASDAQ would provide written notification to us that our common stock is subject to delisting. In the event that we fail to regain compliance with NASDAQ continued listing standards by the expiration of the applicable cure period or any extension
period, NASDAQ will commence suspension and delisting procedures with respect to our common stock, which could impair the value of your investment. If our common stock is delisted from NASDAQ Capital Market in the future, such securities may be
traded over-the-counter on the pink sheets. Such alternative market, however, is generally considered to be less efficient than, and not as broad as, NASDAQ. Accordingly, delisting of our common stock from NASDAQ could have a significant
negative effect on the trading volume, liquidity and market price of our common stock. In addition, the delisting of our common stock could adversely affect our ability to raise capital on terms acceptable to us or at all and could reduce the number
of investors willing to hold or acquire our common stock.
The market price and trading volume of our common stock may be volatile.
The market price of our common stock has exhibited substantial volatility recently. Between February 6, 2016 and February 6, 2017,
the sale price of our common stock as reported on The NASDAQ Capital Market ranged from a low of $1.12 to a high of $45.40. The market price of our common stock could continue to fluctuate significantly for many reasons, including the following
factors:
|
|
|
reports of the results of our clinical trials regarding the safety or efficacy of our product candidates and surrogate markers;
|
|
|
|
announcements of regulatory developments or technological innovations by us or our competitors;
|
|
|
|
announcements of business or strategic transactions such as our recent sales of our marketed products and discontinuation of our commercial operations, or our success in doing so;
|
|
|
|
announcements of legal or regulatory actions against us or any adverse outcome of any such actions;
|
S-24
|
|
|
changes in our relationship with our licensors, licensees and other strategic partners;
|
|
|
|
our quarterly operating results;
|
|
|
|
developments in patent or other technology ownership rights;
|
|
|
|
public concern regarding the safety of our Abstral product or our product candidates;
|
|
|
|
additional funds may not be available on terms that are favorable to us and, in the case of equity financings, may result in dilution to our stockholders;
|
|
|
|
government regulation of drug pricing; and
|
|
|
|
general changes in the economy, the financial markets or the pharmaceutical or biotechnology industries.
|
Factors beyond our control may also have an impact on the price of our stock. For example, to the extent that other companies within our
industry experience declines in their stock prices, our stock price may decline as well.
We are, and in the future may be, subject to legal or
administrative actions that could adversely affect our financial condition and our business.
On June 24, 2016, the U.S.
District Court for the District of Oregon entered a final order and judgment in In re Galena Biopharma, Inc. Derivative Litigation, granting final approval to the settlement awarding attorneys fees of $4.5 million plus costs, which was paid by
our insurance carriers. The settlement included a payment of $15 million in cash by our insurance carriers, which we used to fund a portion of the class action settlement, and cancellation of 1,200,000 outstanding director stock options on a
pre-reverse split basis. The settlement also required that we adopt and implement certain corporate governance measures. The settlement did not include any admission of wrongdoing or liability on the part of us or the individual defendants and
included a full release of us and the current and former officers and directors in connection with the allegations made in the consolidated federal derivative actions and state court derivative actions.
On June 24, 2016, the U.S. District Court for the District of Oregon entered a final order and partial judgment in In re Galena
Biopharma, Inc. Securities Litigation, granting final approval of the settlement awarding attorneys fees of $4.5 million plus costs, which was paid out of the settlement funds. The settlement agreement provided for a payment of $20 million to
the class and the dismissal of all claims against us and our current and former officers and directors in connection with the consolidated federal securities class actions. Of the $20 million settlement payment to the class, $16.7 million was paid
by our insurance carriers and $2.3 million in cash was paid by us on July 1, 2016, along with $1 million in shares of our common stock (480,053 shares on a pre-reverse split basis) issued by us on July 6, 2016. We are responsible for
defense costs and any settlements or judgments incurred for any related opt-out lawsuits.
On December 22, 2016, Galena Biopharma,
Inc. (Galena) and its former Chief Executive Officer (CEO) reached an agreement in principle to a proposed settlement that would resolve an investigation by the staff of the Securities and Exchange Commission (SEC) involving conduct in the period
2012-2014 regarding the commissioning of internet publications by outside promotional firms. Under the terms of the proposed settlement framework, Galena and the former CEO would consent to the entry of an administrative order requiring that we and
the former CEO cease and desist from any future violations of Sections 5(a), 5(b), 5(c), 17(a), and 17(b) of the Securities Act of 1933, as amended, and Section 10(b), 13(a), and 13(b)(2)(A) of the Securities Exchange Act of 1934, as amended,
and various rules thereunder, without admitting or denying the findings in the order. Based upon the proposed settlement framework, the Company will make a $200,000 penalty payment. In addition to other remedies, the proposed settlement framework
would require the former CEO to make a disgorgement and prejudgment interest payment as well as a penalty payment to the Commission. To address the issues raised by the SEC staffs investigation, in addition to previous governance enhancements
we have implemented, we have voluntarily undertaken to implement a number of remedial actions relating to securities offerings and our interactions with investor relations and public relations firms. The proposed settlement is subject to approval by
the Commission and would acknowledge our cooperation in the investigation and confirm our voluntary undertaking to continue that cooperation. If the Commission does not approve the settlement, we may need to enter into further discussions with the
SEC staff to resolve the investigated matters on different terms and conditions. As a result, there can be no assurance as to the final terms of any resolution including its financial impact or any future adjustment to the financial statements. A
special committee of the board of directors has determined in response to an indemnification claim by the former CEO that we are required under Delaware law to indemnify our former CEO for the disgorgement and prejudgment interest payment of
approximately $750,000 that he would be required to pay if and when the settlement is approved by the Commission. Any penalty payment that the former CEO will be required to make in connection with this matter ($600,000 under the proposed settlement
framework) will be the responsibility of the former CEO. In the event the Commission does approve the proposed settlement, the Company may not have available certain exemptions and safe harbor protections under the securities laws.
S-25
Our former commercial operations and development programs are subject to various U.S. federal and
state fraud and abuse laws, including, without limitation, the federal False Claims Act, federal Anti-Kickback Statute, and the federal Sunshine Act. A federal investigation of two of the high-prescribing physicians for Abstral has resulted in the
criminal prosecution of the two physicians for alleged violations of the federal False Claims Act and other federal statutes. The criminal trial began on January 4, 2017. We have received a trial subpoena for documents in connection with that
investigation and we have been in contact with the U.S. Attorneys Office for the Southern District of Alabama, which is handling the criminal trial, and are cooperating in the production of documents. On April 28, 2016, a second
superseding indictment was filed in the criminal case, which added additional information about the defendant physicians and provided information regarding the facts and circumstances involving a rebate agreement between the Company and the
defendant physicians pharmacy as well as their ownership of our stock. Certain former employees have received trial subpoenas to appear at the trial and provide oral testimony. We have agreed to reimburse those former employees
attorneys fees. To our knowledge, we are not a target or subject of that investigation.
There also have been federal and state
investigations of a company that has a product that competes with Abstral in the same therapeutic class, and we have learned that the FDA and other governmental agencies are investigating our Abstral promotion practices. On December 16, 2015,
we received a subpoena issued by the U.S. Attorneys Office for the District of New Jersey requesting the production of a broad range of documents pertaining to our marketing and promotional practices for Abstral. We have been in contact with
the U.S. Attorneys Office for the District of New Jersey and are cooperating in the production of the requested documents. We have come to understand that the investigation being undertaken by the U.S. Attorneys Office for the District
of New Jersey and Department of Justice is a criminal investigation in addition to a civil investigation that could ultimately involve the company as well as one or more former employees. Pursuant to the Companys charter, we are currently
reimbursing certain former employees attorneys fees with respect to the investigation. We are cooperating with the civil and criminal investigation and through our outside counsel we have recently begun preliminary discussions with the
government aimed at the ultimate resolution of the investigation regarding the Company.
We may be subject to legal or administrative
actions as a result of these matters, or the impact of such matters. If we are found to be in violation of the False Claims Act, Anti-Kickback Statute, Patient Protection and Affordable Care Act, or any other applicable state or any federal fraud
and abuse laws, we may be subject to penalties, such as civil and criminal penalties, damages, fines, or an administrative action of exclusion from government health care reimbursement programs. We can make no assurances as to the time or resources
that will need to be devoted to these matters or their outcome, or the impact, if any, that these matters or any resulting legal or administrative proceedings may have on our business or financial condition.
Litigation is inherently uncertain. We have incurred and may continue to incur substantial unreimbursed legal fees and other expenses in
connection with these or other legal and regulatory proceedings that may not qualify for coverage under, or may exceed the limits of, our applicable directors and officers liability insurance policies and could have a material adverse effect on our
financial condition, liquidity, and results of operations. These matters also may distract the time and attention of our officers and directors or divert our other resources away from our ongoing development programs. An unfavorable outcome in any
of these matters could damage our business and reputation or result in additional claims or proceedings against us.
Future sales of substantial
amounts of our common stock, or the possibility that such sales could occur, could adversely affect the market price of our common stock.
Future sales in the public market of shares of our common stock, including shares referred to in the foregoing risk factors or shares issued
upon exercise of our outstanding stock options, or the perception by the market that these sales could occur, could lower the market price of our common stock or make it difficult for us to raise additional capital.
As of September 30, 2016, we had reserved for issuance 518,474 shares of our common stock issuable upon the exercise of outstanding stock
options at a weighted-average exercise price of $46.60 per share (on a post-reverse split adjusted basis) and 2,569,663 shares of our common stock issuable upon the exercise of outstanding warrants at a weighted-average exercise price of $29.20 per
share (on a post-reverse split adjusted basis). Upon exercise of these options and warrants, the underlying shares may be resold into the public market. In the case of outstanding options and warrants that have exercise prices that are below the
market price of our common stock from time to time, our stockholders would experience dilution upon the exercise of these options.
Our outstanding
warrants may result in dilution to our stockholders.
Our outstanding April 2011 warrants to purchase a total of 12,900 shares of
common stock as of September 30, 2016 at a current exercise price of $13.00 per share (on a post-reverse split adjusted basis) contain so-called full-ratchet anti-dilution provisions. Our outstanding December 2012 warrants to purchase 151,565
shares of common stock as of September 30, 2016 at an exercise price of $31.60 per share (on a post-reverse split adjusted basis) contain so-called weighted-average anti-dilution provisions. These anti-dilution provisions may be triggered by
the issuance of the shares being
S-26
offered hereby or upon any future issuance by us of shares of our common stock or common stock equivalents at a price per share below the then-exercise price of the warrants, subject to some
exceptions. The share and per share amounts described above are presented on a post-split basis that was effected November 11, 2016.
To the extent that these anti-dilution provisions are triggered in the future, we would be required to reduce the exercise price of all of the
warrants on either a full-ratchet or weighted-average basis, which would have a dilutive effect on our stockholders.
We may issue preferred stock
in the future, and the terms of the preferred stock may reduce the value of our common stock.
We are authorized to issue up to
5 million shares of preferred stock in one or more series. Our board of directors may determine the terms of future preferred stock offerings without further action by our stockholders. If we issue preferred stock, it could affect stockholder
rights or reduce the market value of our outstanding common stock. In particular, specific rights granted to future holders of preferred stock may include voting rights, preferences as to dividends and liquidation, conversion and redemption rights,
sinking fund provisions, and restrictions on our ability to merge with or sell our assets to a third party.
Anti-takeover provisions of our amended
and restated certificate of incorporation and amended and restated bylaws and provisions of Delaware law could delay or prevent a change of control.
Anti-takeover provisions of our amended and restated certificate of incorporation and amended and restated bylaws may discourage, delay or
prevent a merger or other change of control that stockholders may consider favorable or may impede the ability of the holders of our common stock to change our management and may be constrained by other contractual agreements with third parties.
These provisions of our amended and restated certificate of incorporation and amended and restated bylaws, among other things:
|
|
|
divide our board of directors into three classes, with members of each class to be elected for staggered three-year terms;
|
|
|
|
limit the right of security holders to remove directors;
|
|
|
|
prohibit stockholders from acting by written consent;
|
|
|
|
regulate how stockholders may present proposals or nominate directors for election at annual meetings of stockholders; and
|
|
|
|
authorize our board of directors to issue preferred stock in one or more series, without stockholder approval.
|
In addition, Section 203 of the Delaware General Corporation Law provides that, subject to limited exceptions, persons that acquire, or
are affiliated with a person that acquires, more than 15% of the outstanding voting stock of a Delaware corporation such as our company shall not engage in any business combination with that corporation, including by merger, consolidation or
acquisitions of additional shares for a three-year period following the date on which that person or its affiliate crosses the 15% stock ownership threshold. Section 203 could operate to delay or prevent a change of control of our company.
We have never declared or paid cash dividends on our capital stock and we do not anticipate paying cash dividends in the foreseeable future.
Our business requires significant funding. We currently plan to invest all available funds and future earnings in the development
and growth of our business and do not anticipate paying any cash dividends on our common stock in the foreseeable future, and are prohibited by the terms of our outstanding indebtedness from paying dividends on any common stock, except with the
prior consent of our lenders. As a result, capital appreciation, if any, of our common stock will be our stockholders sole source of potential gain for the foreseeable future.
The terms of our outstanding indebtedness may inhibit potential acquirers.
We are prohibited by the terms of our outstanding indebtedness from disposing of any of our business or property, except with the consent of
our lenders or if we were to prepay the outstanding indebtedness and related fees in accordance with the loan security agreement. Our outstanding indebtedness may inhibit potential acquirers or other interested parties from seeking to acquire all or
a part of our business or assets, and there is no assurance that our lenders would consent to any proposed future transaction that might be beneficial to our stockholders.
S-27
Risks Relating to this Offering
Management will have broad discretion as to the use of the net proceeds of this offering.
We currently intend to use the net proceeds from this offering in our evaluation of strategic alternatives, to fund certain of our clinical
trials of our product candidates, to augment our working capital, and for general corporate purposes. General corporate purposes may include, but are not limited to, payments relating to the settlement and defense costs related to the government
investigations, discontinuation of our commercial operations, winding down the PRESENT Trial, repayment of existing or future indebtedness, and financing of capital expenditures. We have not reserved or allocated amounts for any specific purposes,
however, and we cannot specify with certainty how we will use any net proceeds. Accordingly, our management will have considerable discretion in the application of the net proceeds and you will not have the opportunity, as part of your investment
decision, to assess whether the proceeds are being used appropriately. The net proceeds of this offering may be used for corporate purposes that do not benefit our company or increase our market value. Until the net proceeds are used, they may be
placed in investments that may not produce income or that may lose their value.
Investors will experience immediate and substantial dilution.
You will suffer immediate and substantial dilution. See the Dilution section in this prospectus supplement for more
information about the dilution you will incur in this offering.
You may not be able to resell your warrants.
There is no established trading market for the warrants being offered in this offering, and we do not expect such a market to develop. In
addition, we do not intend to apply for listing of the warrants on any securities exchange or other nationally recognized trading system, and you may not be able to resell your warrants. If your warrants cannot be resold, you will have to depend
upon any appreciation in the value of our common stock over the exercise price of the warrants in order to realize a return on your investment in the warrants.
Investors will have no rights as a common stockholder with respect to their warrants until they exercise their warrants and acquire our common stock.
Until you acquire shares of our common stock upon exercise of your warrants, you will have no rights with respect to the shares
of our common stock underlying such warrants. Upon exercise of your warrants, you will be entitled to exercise the rights of a common stockholder only as to matters for which the record date occurs after the exercise date.
Future sales of our common stock in the public market could cause our stock price to fall.
Sales of a substantial number of shares of our common stock in the public market, or the perception that these sales might occur, could
depress the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities. As of December 31, 2016, we had 15,190,473 shares of common stock outstanding, all of which shares,
other than shares held by our directors and certain officers, were eligible for sale in the public market, subject in some cases to compliance with the requirements of Rule 144, including the volume limitations and manner of sale requirements. In
addition, shares of common stock issuable upon exercise of outstanding options and shares reserved for future issuance under our stock incentive plans will become eligible for sale in the public market to the extent permitted by applicable vesting
requirements and subject in some cases to compliance with the requirements of Rule 144.
NOTE REGARDING FORWARD-LOOKING STATEMENTS
This prospectus supplement, the accompanying prospectus and the other documents we have filed with the SEC that are incorporated herein by
reference contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause our
results to differ materially from those expressed or implied by such forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including any projections of
financing needs, revenue, expenses, earnings or losses from operations, or other financial items, any statements of the plans, strategies and objectives of management for future operations, any statements concerning product research, development and
commercialization plans and timelines, any statements regarding safety and efficacy of product candidates, any statements of expectation or belief and any statements of assumptions underlying any of the foregoing. In addition, forward-looking
statements may contain the words believe, anticipate, expect, estimate, intend, plan, project, will be, will continue, will
result, seek, could, may, might, or any variations of such words or other words with similar meanings. All forward-looking statements attributable to
S-28
us or to persons acting on our behalf are expressly qualified in their entirety by the cautionary statements and risk factors set forth in the Risk Factors section and elsewhere in
this prospectus supplement, in the accompanying prospectus and in our Annual Report on Form 10-K for the year ended December 31, 2015, our subsequent Quarterly Reports on Form 10-Q and our current reports on Form 8-K.
Given these uncertainties, you should not place undue reliance on these forward-looking statements. You should read this prospectus
supplement, the accompanying prospectus and the documents incorporated by reference in this prospectus supplement and the accompanying prospectus with the understanding that our actual future results may be materially different from what we expect.
Except as required by law, we do not undertake any obligation to update or revise any forward-looking statements contained in this prospectus supplement, the accompanying prospectus or such other documents, whether as a result of new information,
future events or otherwise.
S-29
USE OF PROCEEDS
We estimate that the net proceeds from this offering, after underwriting discounts and commissions and estimated offering expenses payable by
us, will be approximately $ million.
Except as otherwise described in any free writing
prospectus that we may authorize to be furnished to you, we currently intend to use the net proceeds from this offering in our evaluation of strategic alternatives, to fund certain of our clinical trials of our product candidates, to augment our
working capital, and for general corporate purposes. General corporate purposes may include, but are not limited to, payments relating to the settlement and defense costs related to the government investigations, discontinuation of our commercial
operations, winding down the PRESENT Trial, repayment of existing or future indebtedness, and financing of capital expenditures.
We have
not determined the amounts we plan to spend on any of the areas listed above or the timing of these expenditures. As a result, our management will have broad discretion to allocate the net proceeds from this offering.
S-30
DIVIDEND POLICY
Our business requires significant funding. We currently plan to invest all available funds and any future earnings in our business and do not
anticipate paying any cash dividends on our common stock in the foreseeable future. We currently are prohibited by the terms of our outstanding indebtedness from paying dividends on our common stock, except with the prior consent of our lenders.
S-31
DILUTION
Our net tangible book value (deficit) as of September 30, 2016 was approximately ($4.1 million), or ($0.38) per share of common stock.
Net tangible book value (deficit) per share is calculated by subtracting our total liabilities from our total tangible assets, which is total assets less intangible assets, and dividing this amount by the number of shares of common stock
outstanding. After giving effect to the sale of shares of common stock in this offering at the public offering price of $ per share and after deducting underwriting discounts
and commissions and estimated offering expenses payable by us, we would have had a net tangible book value (deficit) as of September 30, 2016 of approximately ($ million), or
($ ) per share of common stock. This represents an immediate increase in net tangible book value of $ per share to our existing stockholders and an immediate dilution in net
tangible book value (deficit) of $ per share to investors in this offering. The following table illustrates this dilution:
|
|
|
|
|
|
|
|
|
Public offering price per share
|
|
|
|
|
|
$
|
|
|
Net tangible book value (deficit) per share as of September 30, 2016
|
|
($
|
0.38)
|
|
|
|
|
|
Increase per share attributable to this offering
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As adjusted net tangible book (deficit) per share after this offering
|
|
|
|
|
|
($
|
)
|
|
|
|
|
|
|
|
|
|
|
Net dilution per share to investors in this offering
|
|
|
|
|
|
$
|
|
|
The number of shares of common stock shown above to be outstanding after this offering is based on 10,725,098
shares outstanding as of September 30, 2016 on a post reverse split basis of 1:20 effected November 11, 2016 and excludes as of such date on a post reverse split basis:
|
|
|
33,750 shares held in treasury;
|
|
|
|
518,474 shares of our common stock subject to outstanding options having a weighted-average exercise price of $46.60 per share;
|
|
|
|
543,141 shares of our common stock reserved for issuance in connection with future awards under our 2007 stock incentive plan;
|
|
|
|
20,929 shares of our common stock reserved for future sale under our employee stock purchase plan;
|
|
|
|
2,569,663 shares of our common stock subject to outstanding warrants having a weighted-average exercise price of $29.20 per share; and
|
|
|
|
shares of common stock issuable upon exercise of warrants to be issued in this offering.
|
The
shares of common stock issuable upon the exercise of our outstanding warrants and the exercise price of the warrants are subject to an adjustment in certain circumstances. These anti-dilution provisions would be triggered upon any issuance by us of
shares of our common stock or common stock equivalents at a price per share below the then-exercise price of warrants, subject to some exceptions. Upon consummation of the offering, we anticipate that the exercise price of our outstanding April 2011
warrants to purchase a total of 12,900 shares of common stock as of September 30, 2016 at a current exercise price of $13.00 per share contain so-called full-ratchet anti-dilution provisions and will be adjusted downward to
$ per share. Our outstanding December 2012 warrants to purchase 151,565 shares of common stock as of September 30, 2016 at exercise prices of $31.60, respectively, per share contain so-called weighted average
anti-dilution provisions. Upon consummation of the offering, we anticipate that the exercise price of our outstanding December 2012 warrants to purchase a total of 151,565 shares of common stock as of September 30, 2016 will be adjusted
downward from $31.60 to $ per share.
To the extent our outstanding options and warrants
are exercised, you may experience further dilution. The above illustration of dilution per share to investors participating in this offering assumes no exercise of outstanding options or outstanding warrants to purchase shares of our common stock.
The illustration also assumes no further issuance of shares of our common stock in payment of contingent consideration to holders of our outstanding contingent value rights or others. The exercise of outstanding options and warrants having an
exercise price less than the offering price of the shares in this offering, or our payment to our contingent value rights holders or others of common shares valued at less than the offering price of shares in this offering, would further increase
dilution to investors in this offering.
S-32
DESCRIPTION OF OUR SECURITIES
We are offering units, consisting of an aggregate of
shares of common stock and warrants to purchase an aggregate of shares of common stock. Each unit
consists of one share of common stock and a warrant to purchase of a share of common stock at an exercise price of $ per whole share. The units will not
be issued or certificated. The shares of common stock and the warrants are immediately separable and will be issued separately. This prospectus supplement also relates to the offering of the shares of common stock issuable upon exercise of the
warrants being offered in this offering.
Common Stock
As of February 6, 2017, 18,828,222 shares of our common stock were issued and outstanding.
Each holder of our common stock is entitled to one vote for each share of common stock held on all matters submitted to a vote of
stockholders. Common stockholders are not entitled to cumulative voting in the election of directors by our certificate of incorporation. This means that the holders of a majority of the shares voted will be able to elect all of the directors then
standing for election. Subject to preferences that may apply to shares of preferred stock outstanding at the time, the holders of outstanding shares of our common stock are entitled to receive dividends out of assets legally available at the times
and in the amounts that our board of directors may determine from time to time.
Upon our liquidation, dissolution or winding-up, the
holders of our common stock will be entitled to share ratably in all assets remaining after payment of all liabilities and the liquidation preferences of any series of capital stock ranking senior to the common stock upon liquidation. Holders of
common stock have no preemptive or conversion rights or other subscription rights. There are no redemption or sinking fund provisions applicable to the common stock. All outstanding shares of common stock are fully paid and nonassessable, and the
shares of common stock to be issued under this prospectus supplement, when they are paid for, will be fully paid and nonassessable.
Our
common stock is listed on The NASDAQ Capital Market under the symbol GALE. The transfer agent of our common stock is Computershare Trust Company, N.A.
Warrants
Form
. The warrants will
be issued under a warrant agreement to be entered into between us and the warrant agent.
Exercisability
. The warrants will be
exercisable upon issuance and will expire on the five-year anniversary of issuance. The warrants will be exercisable, at the option of each holder, in whole or in part by delivering to us a duly executed exercise notice and payment in full of the
exercise price within three Trading Days in available funds for the number of shares of common stock purchased upon such exercise. If a registration statement registering the issuance or the resale of the shares of common stock underlying the
warrants under the Securities Act is not effective or available, the holder may, in its sole discretion, elect to exercise the warrant through a cashless exercise, in which case the holder would receive upon such exercise the net number of shares of
common stock determined according to the formula set forth in the warrant. No fractional shares of common stock will be issued in connection with the exercise of a warrant. In lieu of fractional shares, we will pay the holders an amount in cash
equal to the fractional amount multiplied by the current market price of our common stock.
Exercise Limitation
. A holder will not
have the right to exercise any portion of the warrant if the holder (together with affiliates) would beneficially own in excess of 4.99% of the number of shares of our common stock outstanding immediately after giving effect to the exercise, as such
percentage of ownership is determined in accordance with the terms of the warrants. However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99% upon at least 61 days prior notice from the holder
to us.
Exercise Price
. The exercise price per whole share of common stock purchasable upon exercise of the warrants is
$ . The exercise price is subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our common stock and also upon any
distribution of assets, including cash, stock or other property, to our stockholders.
Transferability
. Subject to applicable laws,
the warrants may be offered for sale, sold, transferred or assigned without our consent.
Exchange Listing
. The warrants will not
be listed on The NASDAQ Capital Market or other securities exchange or nationally recognized trading system.
S-33
Fundamental Transactions
. In the event of a fundamental transaction, as described in the
warrants and generally including any merger or consolidation with or into another entity, as a result of which the holders of our outstanding voting securities as of immediately prior to such merger or consolidation hold less than a majority of the
outstanding voting securities of the surviving or successor entity as of immediately after such merger or consolidation or a sale, transfer or other disposition of all or substantially all our property, assets or business to another person or
entity, the holders of the warrants will be entitled to receive upon exercise of the warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised the warrant immediately prior to such
fundamental transactions.
In addition in the event of any fundamental transaction the holder of the warrant has the right, in lieu of
receiving the consideration described in the preceding paragraph, to require us to purchase the warrant for an amount of cash backed on the value of the remaining unexercised portion of the warrant determined in accordance with the Black Scholes
option pricing model.
Pro Rata Distributions
. In the event that we distribute debt, securities, rights or warrants to purchase
securities or other assets to holders of common stock, then upon exercise of the warrants, the holders will be entitled to receive the same distribution they would have received had they exercised the warrants immediately prior to the distribution.
Rights as a Stockholder
. Except as otherwise provided in the warrants or by virtue of such holders ownership of shares of
our common stock, the holder of a warrant does not have the rights or privileges of a holder of our common stock, including any voting rights, until the holder exercises the warrant.
Warrant Agent
. Computershare Trust Company, N.A. will act as our warrant agent for the warrants.
S-34
UNDERWRITING
We have entered into an underwriting agreement with Canaccord Genuity Inc., or Canaccord Genuity, as the sole underwriter. The underwriting
agreement provides for the purchase of a specific number of units comprised of shares of common stock and warrants to purchase common stock by the underwriter. Subject to the terms and conditions of the underwriting agreement, the underwriter has
agreed to purchase the number of units set forth opposite its name below:
|
|
|
Underwriter
|
|
Number of Units
|
Canaccord Genuity Inc.
|
|
|
Total
|
|
|
The underwriter has agreed to purchase all of the units offered by this prospectus supplement if any are
purchased.
The shares of common stock and the warrants to purchase common stock offered hereby should be ready for delivery on or about
February , 2017 against payment in immediately available funds.
The underwriter is
offering the units subject to various conditions and may reject all or part of any order. The underwriter has advised us that the underwriter proposes to offer the units directly to the public at the public offering price that appears on the cover
page of this prospectus supplement. After the units are released for sale to the public, the underwriter may change the offering price and other selling terms at various times.
The following table provides information regarding the amount of the discounts and commissions to be paid to the underwriter by us, before
expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Per Unit
|
|
|
|
|
Total
|
|
Public offering price
|
|
$
|
|
|
|
|
|
$
|
|
|
|
|
Underwriting discounts and commissions
|
|
$
|
|
|
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds, before expenses to us
|
|
$
|
|
|
|
|
|
$
|
|
|
|
|
We estimate that our total expenses of the offering, excluding the underwriting discounts and commissions,
will be approximately $ , which includes $100,000 that we have agreed to reimburse the underwriter for the fees and expenses incurred by it in connection with the offering.
We have agreed to indemnify the underwriter against certain liabilities, including liabilities under the Securities Act of 1933.
We and our officers and directors have agreed to a 90-day lock-up with respect to shares of our common stock and other of our
securities that they beneficially own, including securities that are convertible into shares of common stock and securities that are exchangeable or exercisable for shares of common stock. This means that, subject to certain exceptions, for a period
of 90 days following the date of this prospectus supplement, we and such persons may not offer, sell, pledge or otherwise dispose of these securities without the prior written consent of Canaccord Genuity.
In order to facilitate the offering of the units, the underwriter may engage in transactions that stabilize, maintain or otherwise affect the
price of our common stock. Specifically, the underwriter may sell more units than it is obligated to purchase under the underwriting agreement, creating a short position. The underwriter must close out any short position by purchasing shares of
common stock in the open market. A short position may be created if the underwriter is concerned that there may be downward pressure on the price of the common stock in the open market after pricing that could adversely affect investors who
purchased in this offering. As an additional means of facilitating this offering, the underwriter may bid for, and purchase, shares of our common stock in the open market to stabilize the price of the common stock. These activities may raise or
maintain the market price of our common stock above independent market levels or prevent or slow a decline in the market price of our common stock. The underwriter is not required to engage in these activities, and may end any of these activities at
any time.
Neither we nor the underwriter make any representation or prediction as to the effect that the transactions described above may
have on the price of our common stock. These transactions may occur on The NASDAQ Capital Market or otherwise. If such transactions are commenced, they may be discontinued without notice at any time.
Electronic Delivery of Prospectus Supplement: A prospectus supplement in electronic format may be delivered to potential investors by the
underwriter. The prospectus supplement in electronic format will be identical to the paper version of such prospectus supplement. Other than the prospectus supplement in electronic format, the information on any underwriters website and any
information contained in any other website maintained by an underwriter is not part of this prospectus supplement, the accompanying prospectus or the registration statement of which this prospectus supplement and the accompanying prospectus form a
part.
S-35
From time to time in the ordinary course of its businesses, the underwriter and certain of its
affiliates have engaged or may in the future engage, in investment banking transactions with us and our affiliates for which it has received, or in the future may receive, customary fees.
NOTICE TO INVESTORS
Investors are
advised to contact their legal, financial or tax advisers to obtain an independent assessment of the financial and tax consequences of an investment in units.
NOTICE TO NON-U.S. INVESTORS
BELGIUM
The offering is exclusively conducted under applicable private placement exemptions and therefore it has not been and will not be notified to,
and this document or any other offering material relating to the units has not been and will not be approved by, the Belgian Banking, Finance and Insurance Commission (Commission bancaire, financière et des assurances/Commissie voor het
Bank, Financie en Assurantiewezen). Any representation to the contrary is unlawful.
Each underwriter has undertaken not to offer
sell, resell, transfer or deliver directly or indirectly, any units, or to take any steps relating/ancillary thereto, and not to distribute or publish this document or any other material relating to the units or to the offering in a manner which
would be construed as: (a) a public offering under the Belgian Royal Decree of 7 July 1999 on the public character of financial transactions; or (b) an offering of securities to the public under Directive 2003/71/EC which triggers an
obligation to publish a prospectus in Belgium. Any action contrary to these restrictions will cause the recipient and us to be in violation of the Belgian securities laws.
FRANCE
Neither this prospectus
supplement nor any other offering material relating to the units has been submitted to the clearance procedures of the Autorité des marchés financiers in France. The units have not been offered or sold and will not be offered or sold,
directly or indirectly, to the public in France. Neither this prospectus supplement nor any other offering material relating to the units has been or will be: (a) released, issued, distributed or caused to be released, issued or distributed to
the public in France; or (b) used in connection with any offer for subscription or sale of the units to the public in France. Such offers, sales and distributions will be made in France only: (i) to qualified investors (investisseurs
qualifiés) and/or to a restricted circle of investors (cercle restreint dinvestisseurs), in each case investing for their own account, all as defined in and in accordance with Articles L.411-2, D.411-1, D.411-2, D.734-1, D.744-1,
D.754-1 and D.764-1 of the French Code monétaire et financier; (ii) to investment services providers authorised to engage in portfolio management on behalf of third parties; or (iii) in a transaction that, in accordance with article
L.411-2-II-1°-or-2°-or 3° of the French Code monétaire et financier and article 211-2 of the General Regulations (Règlement Général) of the Autorité des marchés financiers, does not constitute a
public offer (appel public à lépargne). Such units may be resold only in compliance with Articles L.411-1, L.411-2, L.412-1 and L.621-8 through L.621-8-3 of the French Code monétaire et financier.
UNITED KINGDOM / GERMANY / NORWAY / THE NETHERLANDS
In relation to each Member State of the European Economic Area which has implemented the Prospectus Directive (each, a Relevant Member
State) an offer to the public of any units which are the subject of the offering contemplated by this prospectus supplement may not be made in that Relevant Member State other than the offers contemplated in this prospectus supplement in
name(s) of Member State(s) where prospectus will be approved or passported for the purposes of a non-exempt offer once this prospectus supplement has been approved by the competent authority in such Member State and published and passported in
accordance with the Prospectus Directive as implemented in name(s) of relevant Member State(s) except that an offer to the public in that Relevant Member State of any units may be made at any time under the following exemptions under the Prospectus
Directive, if they have been implemented in that Relevant Member State:
(a) to legal
entities which are authorised or regulated to operate in the financial markets or, if not so authorised or regulated, whose corporate purpose is solely to invest in securities;
(b) to any legal entity which has two or more of (1) an average of at least 250 employees
during the last financial year; (2) a total balance sheet of more than 43,000,000 and (3) an annual net turnover of more than 50,000,000, as shown in its last annual or consolidated accounts;
(c) by the representative to fewer than 100 natural or legal persons (other than qualified
investors as defined in the Prospectus Directive); or
(d) in any other circumstances
falling within Article 3(2) of the Prospectus Directive, provided that no such offer of units shall result in a requirement for the publication by the Company or any underwriter of a prospectus pursuant to Article 3 of the Prospectus Directive.
S-36
For the purposes of this provision, the expression an offer to the public in relation
to any units in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and any units to be offered so as to enable an investor to decide to purchase any units, as the same
may be varied in that Member State by any measure implementing the Prospectus Directive in that Member State and the expression Prospectus Directive means Directive 2003/71/EC and includes any relevant implementing measure in each
Relevant Member State.
This prospectus supplement and any other material in relation to the units is only being distributed to, and is
only directed at, persons in the United Kingdom that are qualified investors within the meaning of Article 2(1)(e) of the Prospective Directive (qualified investors) that also (i) have professional experience in matters relating to
investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended, or the Order, (ii) who fall within Article 49(2)(a) to (d) of the Order or (iii) to whom it may
otherwise lawfully be communicated (all such persons together being referred to as relevant persons). The units are only available to, and any invitation, offer or agreement to purchase or otherwise acquire such units will be engaged in
only with, relevant persons. This prospectus supplement and its contents are confidential and should not be distributed, published or reproduced (in whole or in part) or disclosed by recipients to any other person in the United Kingdom. Any person
in the United Kingdom that is not a relevant person should not act or rely on this prospectus supplement or any of its contents.
ISRAEL
In the State of Israel, the units offered hereby may not be offered to any person or entity other than the following:
(a) a fund for joint investments in trust (i.e., mutual fund), as such term is defined in the
Law for Joint Investments in Trust, 5754-1994, or a management company of such a fund;
(b) a provident fund as defined in Section 47(a)(2) of the Income Tax Ordinance of the
State of Israel, or a management company of such a fund;
(c) an insurer, as defined in the
Law for Oversight of Insurance Transactions, 5741-1981, (d) a banking entity or satellite entity, as such terms are defined in the Banking Law (Licensing), 5741-1981, other than a joint services company, acting for their own account or for the
account of investors of the type listed in Section 15A(b) of the Securities Law 1968;
(d) a company that is licensed as a portfolio manager, as such term is defined in
Section 8(b) of the Law for the Regulation of Investment Advisors and Portfolio Managers, 5755-1995, acting on its own account or for the account of investors of the type listed in Section 15A(b) of the Securities Law 1968;
(e) a company that is licensed as an investment advisor, as such term is defined in
Section 7(c) of the Law for the Regulation of Investment Advisors and Portfolio Managers, 5755-1995, acting on its own account;
(f) a company that is a member of the Tel Aviv Stock Exchange, acting on its own account or for
the account of investors of the type listed in Section 15A(b) of the Securities Law 1968;
(g) an underwriter fulfilling the conditions of Section 56(c) of the Securities Law,
5728-1968;
(h) a venture capital fund (defined as an entity primarily involved in
investments in companies which, at the time of investment, (i) are primarily engaged in research and development or manufacture of new technological products or processes and (ii) involve above-average risk);
(i) an entity primarily engaged in capital markets activities in which all of the equity owners
meet one or more of the above criteria; and
(j) an entity, other than an entity formed for
the purpose of purchasing units in this offering, in which the shareholders equity (including pursuant to foreign accounting rules, international accounting regulations and U.S. generally accepted accounting rules, as defined in the Securities Law
Regulations (Preparation of Annual Financial Statements), 1993) is in excess of NIS 250 million.
S-37
Any offeree of the units offered hereby in the State of Israel shall be required to submit
written confirmation that it falls within the scope of one of the above criteria. This prospectus supplement will not be distributed or directed to investors in the State of Israel who do not fall within one of the above criteria.
ITALY
The offering of the units
offered hereby in Italy has not been registered with the Commissione Nazionale per la Società e la Borsa (CONSOB) pursuant to Italian securities legislation and, accordingly, the units offered hereby cannot be offered, sold or
delivered in the Republic of Italy (Italy) nor may any copy of this prospectus supplement or any other document relating to the units offered hereby be distributed in Italy other than to professional investors (operatori qualificati) as
defined in Article 31, second paragraph, of CONSOB Regulation No. 11522 of 1 July, 1998 as subsequently amended. Any offer, sale or delivery of the units offered hereby or distribution of copies of this prospectus supplement or any other
document relating to the units offered hereby in Italy must be made:
(a) by an investment
firm, bank or intermediary permitted to conduct such activities in Italy in accordance with Legislative Decree No. 58 of 24 February 1998 and Legislative Decree No. 385 of 1 September 1993 (the Banking Act);
(b) in compliance with Article 129 of the Banking Act and the implementing guidelines of the
Bank of Italy; and
(c) in compliance with any other applicable laws and regulations and
other possible requirements or limitations which may be imposed by Italian authorities.
SWEDEN
This prospectus supplement has not been nor will it be registered with or approved by Finansinspektionen (the Swedish Financial Supervisory
Authority). Accordingly, this prospectus supplement may not be made available, nor may the units offered hereunder be marketed and offered for sale in Sweden, other than under circumstances which are deemed not to require a prospectus under the
Financial Instruments Trading Act (1991: 980).
SWITZERLAND
The units being offered pursuant to this prospectus supplement will not be offered, directly or indirectly, to the public in Switzerland and
this prospectus supplement does not constitute a public offering prospectus as that term is understood pursuant to art. 652a or art. 1156 of the Swiss Federal Code of Obligations. We have not applied for a listing of the units being offered pursuant
to this prospectus supplement on the SWX Swiss Exchange or on any other regulated securities market, and consequently, the information presented in this prospectus supplement does not necessarily comply with the information standards set out in the
relevant listing rules. The units being offered pursuant to this prospectus supplement have not been registered with the Swiss Federal Banking Commission as foreign investment funds, and the investor protection afforded to acquirers of investment
fund certificates does not extend to acquirers of units.
CANADA
The units may be sold in Canada only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as
defined in National Instrument 45-106 Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant
Obligations. Any resale of the units must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws.
Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this
prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchasers
province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchasers province or territory for particulars of these rights or consult with a legal advisor.
Pursuant to section 3A.3 of National Instrument 33-105 Underwriting Conflicts (NI 33-105), the underwriter is not required to comply with the
disclosure requirements of NI 33-105 regarding underwriter conflicts of interest in connection with this offering.
S-38
LEGAL MATTERS
Paul Hastings LLP, San Francisco, California, has rendered an opinion with respect to the validity of the securities offered by this
prospectus supplement. The underwriter is being represented in connection with this offering by Goodwin Procter, LLP, New York, New York.
EXPERTS
Our consolidated financial statements appearing in our Annual Report on Form 10-K for the year ended December 31, 2015, and the effectiveness
of our internal control over financial reporting as of December 31, 2015, have been audited by Moss Adams LLP, an independent registered public accounting firm, as stated in their reports, which are incorporated herein by reference. Such
consolidated financial statements have been so incorporated in reliance upon the report of such firm given upon their authority as experts in accounting and auditing.
WHERE YOU CAN FIND MORE INFORMATION
We have filed a registration statement on Form S-3 with the SEC under the Securities Act of 1933. This prospectus supplement is part of the
registration statement, but the registration statement includes and incorporates by reference additional information and exhibits. We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and
copy the registration statement and any other document we file with the SEC at the public reference room maintained by the SEC at 100 F Street, N.E., Washington, D.C. 20549. You may obtain information on the operation of the public reference room by
calling the SEC at 1-800-SEC-0330. The SEC also maintains a web site that contains reports, proxy and information statements and other information regarding companies, such as ours, that file documents electronically with the SEC. The address of
that site on the world wide web is http://www.sec.gov. The information on the SECs web site is not part of this prospectus supplement, and any references to this web site or any other web site are inactive textual references only.
INCORPORATION OF DOCUMENTS BY REFERENCE
The SEC permits us to incorporate by reference the information contained in documents we file with the SEC, which means that we
can disclose important information to you by referring you to those documents rather than by including them in this prospectus supplement. Information that is incorporated by reference is considered to be part of this prospectus supplement, and you
should read it with the same care that you read this prospectus supplement. Later information that we file with the SEC will automatically update and supersede the information that is either contained, or incorporated by reference, in this
prospectus supplement, and will be considered to be a part of this prospectus supplement from the date those documents are filed.
We
incorporate by reference into this prospectus supplement the following documents and information filed with the SEC:
|
|
|
our Annual Reports on Form 10-K and Form 10-K/A for the year ended December 31, 2015, which was filed on March 10, 2016, and amended on March 11, 2016, April 15, 2016 and April 29, 2016
respectively;
|
|
|
|
our Quarterly Reports on Form 10-Q for the quarter ended March 31, 2016, which was filed on May 10, 2016, for the quarter ended June 30, 2016, which was filed on August 9, 2016, and for the quarter
ended September 30, 2016, which was filed on November 9, 2016;
|
|
|
|
our Current Reports on Form 8-K, which were filed on January 7, 2016, February 16, 2016, February 25, 2016, April 7, 2016, April 26, 2016, June 28, 2016, June 29, 2016, July 8,
2016, July 12, 2016, July 18, 2016, August 9, 2016 (excluding items 2.02, 7.01 and 9.01), August 12, 2016, August 16, 2016, August 22, 2016, August 23, 2016, September 8, 2016, October 6, 2016,
October 26, 2016, October 31, 2016, November 3, 2016, December 1, 2016, December 22, 2016, January 9, 2017, January 31, 2017 and February 7, 2017, respectively;
|
|
|
|
our definitive Proxy Statement on Schedule 14A filed on June 3, 2016, in connection with the 2016 annual meeting of stockholders and definitive Proxy Statement on Schedule 14A filed on September 21, 2016, in
connection with the special meeting of stockholders on October 21, 2016; and
|
|
|
|
the description of our common stock and related rights contained in our registration statement on Form 8-A (File No. 001-33958), including any amendment or report filed for the purpose of updating such description.
|
We also incorporate by reference into this prospectus supplement all additional documents that we file with the SEC under
the terms of Section 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934 that are made after the date of this prospectus and before the termination of the offering of securities offered by this prospectus supplement. We are not,
however, incorporating, in each case, any documents or information that we are deemed to furnish and not file in accordance with SEC rules.
S-39
You may request a copy of any of the documents incorporated by reference into this prospectus
supplement, at no cost, by writing or telephoning us at the following address: Galena Biopharma, Inc., 2000 Crow Canyon Place, Suite 380, San Ramon, California 94583, Attention: Investor Relations, Phone: (855) 855-4253. We will not send
exhibits to any documents, unless the exhibits are specifically incorporated by reference into the document.
S-40
PROSPECTUS
GALENA BIOPHARMA, INC.
$100,000,000
Common
Stock
Preferred Stock
Warrants
Rights
Units
We may, from
time to time, offer and sell shares of common stock, shares of preferred stock, warrants or rights, either separately or in units, in one or more offerings. The preferred stock and warrants may be convertible into or exercisable or exchangeable for
common stock or preferred stock. The rights may be exercisable for common stock or preferred stock. We will specify in the accompanying prospectus supplement more specific information about any such offering. The aggregate initial offering price of
all securities sold under this prospectus will not exceed $100,000,000, including the U.S. dollar equivalent if the public offering of any such securities is denominated in one or more foreign currencies, foreign currency units or composite
currencies.
We may offer these securities for sale directly to investors or through underwriters, dealers or agents. We will set forth
the names of any underwriters, dealers or agents and their compensation in the accompanying prospectus supplement.
This prospectus may
not be used to sell any of these securities unless accompanied by a prospectus supplement.
Our common stock is traded on The NASDAQ
Capital Market under the symbol GALE. On December 3, 2015, the last reported sale price of our common stock on The NASDAQ Capital Market was $1.45 per share.
Investing in our securities involves risks. See the section entitled
Risk Factors
in the
accompanying prospectus supplement and in the documents we incorporate by reference in this prospectus.
NEITHER THE SECURITIES AND
EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE ADEQUACY OR ACCURACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.
The date of this prospectus is December 22, 2015
Prospectus No. 1
TABLE OF CONTENTS
ABOUT THIS PROSPECTUS
This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission, or SEC, using a
shelf registration, or continuous offering, process. Under this shelf registration process, we may, from time to time, offer and sell shares of common stock, shares of preferred stock, warrants or rights, either separately or in units,
in one or more offerings with a maximum aggregate offering price of $100,000,000.
This prospectus provides you with a general description
of the securities we may offer. Each time we sell securities, we will provide a prospectus supplement that will contain specific information about the terms of that offering and the offered securities. Any prospectus supplement may also add, update
or change information contained in this prospectus. Any statement that we make in this prospectus will be modified or superseded by any inconsistent statement made by us in a prospectus supplement. The registration statement we filed with the SEC
includes exhibits that provide more detail of the matters discussed in this prospectus. You should read this prospectus and the related exhibits filed with the SEC and any prospectus supplement, together with additional information described under
the heading Where You Can Find More Information, before making your investment decision.
Unless otherwise indicated,
information contained or incorporated by reference in this prospectus concerning our industry, including our general expectations and market opportunity, is based on information from our own management estimates and research, as well as from
industry and general publications and research, surveys and studies conducted by third parties. Management estimates are derived from publicly available information, our knowledge of our industry and assumptions based on such information and
knowledge, which we believe to be reasonable. In addition, assumptions and estimates of our and our industrys future performance are necessarily uncertain due to a variety of factors, including those referred to in Risk Factors
below in this prospectus. These and other factors could cause our future performance to differ materially from our assumptions and estimates.
NeuVax is our trademark used in this prospectus. This prospectus also includes the
Zuplenz
®
trademark and Abstral
®
and other trademarks, trade names and service marks that are the property of other organizations but in
certain instances have been licensed to us. Solely for convenience, trademarks and trade names referred to in this prospectus sometimes appear without the
®
and symbols, but those
references are not intended to indicate that we will not assert, to the fullest extent under applicable law, our rights, or that the applicable owner will not assert its rights, to these trademarks and trade names.
NOTE REGARDING FORWARD-LOOKING STATEMENTS
This prospectus and the other documents we have filed with the SEC that are incorporated herein by reference contain forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from
those expressed or implied by such forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including any projections of financing needs, revenue, expenses,
earnings or losses from operations, or other financial items, any statements of the plans, strategies and objectives of management for future operations, any statements concerning product research, development and commercialization plans and
timelines, any statements regarding safety and efficacy of product candidates, any statements of expectation or belief and any statements of assumptions underlying any of the foregoing. In addition, forward-looking statements may contain the words
believe, anticipate, expect, estimate, intend, plan, project, will be, will continue, will result, seek,
could, may, might, or any variations of such words or other words with similar meanings. All forward-looking statements attributable to us or to persons acting on our behalf are expressly qualified in their
entirety by the cautionary statements and risk factors set forth under Risk Factors and elsewhere in this prospectus and set forth in our Form 10-K for the year ended December 31, 2014 and subsequent Quarterly Reports on Form 10-Q
filed with the SEC. See Where You Can Find More Information and Incorporation of Certain Documents by Reference in this prospectus for information on how to access or obtain our reports filed with the SEC.
Given their inherent uncertainty, you should not place undue reliance on these forward-looking statements. You should read this prospectus and
the documents that we reference in this prospectus with the understanding that our actual future results may be materially different from what we expect. Except as required by law, we do not undertake any obligation to update or revise any
forward-looking statements contained in this prospectus, whether as a result of new information, future events or otherwise.
RISK FACTORS
Investing in our securities involves significant risks. The
prospectus supplement relating to a particular offering will contain a discussion of risks applicable to an investment in the securities offered. Prior to making a decision about investing in our securities, you should carefully consider the
specific factors discussed under the heading Risk Factors in the applicable prospectus supplement together with all of the other information contained in the prospectus supplement or appearing or incorporated by reference in this
prospectus.
1
Prospectus No. 1
ABOUT GALENA
Overview
Galena Biopharma, Inc.
(we, us, our, Galena or the company) is a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical
needs. Galenas development portfolio is focused primarily on addressing the rapidly growing patient populations of cancer survivors by harnessing the power of the immune system to prevent cancer recurrence. The Companys pipeline consists
of multiple mid- to late-stage clinical assets, including novel cancer immunotherapy programs led by NeuVax (nelipepimut-S) and GALE-301. NeuVax is currently in a pivotal, Phase 3 clinical trial with several concurrent Phase 2 trials ongoing
both as a single agent and in combination with other therapies. GALE-301 is in a Phase 2a clinical trial in ovarian and endometrial cancers and in a Phase 1b given sequentially with GALE-302.
We are seeking to build value for shareholders through pursuit of the following objectives:
|
|
|
Develop novel cancer immunotherapies to address unmet medical needs through the use of peptide-based vaccines targeting well-established tumor antigens. One of our key strategies is to target the adjuvant, minimum
residual disease setting, in high risk patients who are more likely to benefit from treatment via immunotherapy. Our immunotherapy programs are currently targeting two key areas: secondary prevention to seek to significantly decrease the risk of
disease recurrence in breast cancer, gastric cancer, endometrial and ovarian cancers; and a planned trial positioning earlier in the breast cancer treatment spectrum via primary prevention.
|
|
|
|
Expand our development pipeline by enhancing the clinical and geographic footprint of our technologies. We can accomplish this through the initiation of new clinical trials as well as through acquisition of additional
development stage products in related oncology indications.
|
|
|
|
Leverage valuable partnerships and collaborations, as well as investigator-sponsored trial arrangements, to maximize the scope of potential clinical opportunities in a cost effective and efficient manner.
|
|
|
|
Focus our resources on our valuable and expanding clinical development programs. On November 19, 2015, we sold our Abstral
®
(fentanyl) Sublingual Tablets
product and related assets and we have determined to sell or otherwise dispose of our Zuplenz
®
(ondansetron) Oral Soluble Film product and related assets and to cease our commercial operations
to seek to maximize value to our shareholders.
|
The chart below summarizes the current status of our clinical development
pipeline:
2
Prospectus No. 1
Novel Cancer Immunotherapies
Our targeted cancer immunotherapy approach is currently based upon two key areas: preventing secondary recurrence of cancer, which is becoming
increasingly important as the number of cancer survivors continues to grow; and, positioning earlier in the breast cancer treatment spectrum via primary prevention. Once a patients tumor becomes metastatic, the outcome is most often fatal,
making the prevention of recurrence a potentially critical component of overall patient care. Our programs primarily target patients in the adjuvant (after-surgery) setting who have relatively healthy immune systems, but may still have minimal
residual disease. Minimal residual disease, or single cancer cells (occult cancer cells) or micrometastasis, are undetectable by current radiographic scanning technologies, but we know can result in disease recurrence.
Our therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating
factor (rhGM-CSF), and work by harnessing the patients own immune system to seek out and attack any residual cancer cells. Using peptide immunogens has many potential clinical advantages, including a favorable safety profile, since these drugs
may lack the toxicities typical of most cancer therapies. They also have the potential to evoke long-lasting protection through activation of the immune system and a convenient, intradermal mode of delivery. We are currently engaged in multiple
clinical trials with NeuVax (nelipepimut-S), GALE-301, and GALE-302, targeting the prevention of recurrence in breast, gastric, ovarian and endometrial cancers.
NeuVax (nelipepimut-S)
NeuVax (nelipepimut-S), our lead product candidate, is a cancer immunotherapy targeting human epidermal growth factor receptor (HER2)
expressing cancers. NeuVax is the immunodominant nonapeptide derived from the extracellular domain of the HER2 protein, a well-established and validated target for therapeutic intervention in breast and gastric carcinomas. The NeuVax vaccine is
combined with GM-CSF for injection under the skin, or intradermal administration. Data has shown that an increased presence of circulating tumor cells (CTCs) may predict Disease Free Survival (DFS) and Overall Survival (OS)suggesting a
dormancy of isolated micrometastases, which, over time, may lead to recurrence. After binding to the specific HLA molecules on antigen presenting cells, the nelipepimut-S sequence stimulates specific cytotoxic T lymphocyte (CTLs). These activated
CTLs recognize, neutralize and destroy, through cell lysis, HER2 expressing cancer cells, including occult cancer cells and micrometastatic foci. The nelipepimut immune response can also generate CTLs to other immunogenic peptides through inter- and
intra-antigenic epitope spreading.
Breast Cancer
: According to the National Cancer Institute, over 230,000 women in the U.S. are
diagnosed with breast cancer annually. While improved diagnostics and targeted therapies have decreased breast cancer mortality in the U.S., metastatic breast cancer remains incurable. Approximately 75% of breast cancer patients have tissue test
positive for some increased amount of the HER2 receptor, which is associated with disease progression and decreased survival. Only approximately 20% to 30% of all breast cancer patientsthose with HER2 immunohistochemistry (IHC) 3+ disease, or
IHC 2+ and fluorescence in situ hybridization (FISH) positivehave a HER2 directed, approved treatment option available. This leaves the majority of breast cancer patients with low-to-intermediate HER2 IHC 1+/2+ ineligible for therapy and
without an effective targeted treatment option to prevent cancer recurrence.
We have multiple trials currently ongoing for NeuVax. For
our pivotal, Phase 3 PRESENT (
P
revention of
R
ecurrence in
E
arly-
S
tage, Node- Positive Breast Cancer with Low to Intermediate HER2
E
xpression with
NeuVax T
reatment) trial, NeuVax is targeting the
30,000-40,000 of the 230,000 female breast cancer patients annually diagnosed in the U.S. who are at a higher risk of their breast cancer recurring, which we refer to as disease recurrence, after achieving no evidence of
disease (NED) status, (or becoming a survivor) with standard-of-care therapy (surgery, chemotherapy, radiation). These high-risk patients have a particular molecular signature and disease status: HER2 IHC 1+/2+ (oncoprotein
associated with aggressive tumor growth), node positive (disease present in the axillary lymph nodes prior to surgery), and HLA A2/A3 (human leukocyte antigen from A2/A3 patients who have the same loci of genes which represents approximately 65% of
the population). Up to 25% of resectable, node-positive breast cancer patients, having no radiographic evidence of disease following surgery and adjuvant chemo/radiation therapy, are expected to relapse within three years following diagnosis. The
prognosis upon recurrence is very poor. These cancer patients presumably still had isolated, undetected tumor CTCs that led to a recurrence of cancer in the breast (local recurrence) or in another location (metastatic disease). In addition to our
Phase 3 trial, we currently have two additional Phase 2 breast cancer trials ongoing with NeuVax in combination with trastuzumab (Herceptin
®
; Genentech/Roche) targeting the prevention of
recurrence in expanded indications.
We also recently announced our intent to initiate a Phase 2 trial with NeuVax as a single agent in
patients with ductal carcinoma in situ (DCIS) in collaboration with the National Cancer Institute (NCI), potentially positioning NeuVax earlier in the treatment cycle towards primary prevention. The trial will have an immunological endpoint
evaluating NeuVax peptide-specific cytotoxic T lymphocyte (CTL; CD8+ T cell) response in vaccinated patients. DCIS, is defined by the NCI as a noninvasive condition in which abnormal cells are found in the lining of a breast duct, and is the most
common type of breast cancer. The abnormal cells have not spread outside the duct to other tissues in the breast. In some cases, DCIS may become invasive cancer and spread to other tissues, and at this time, there is no way to know which lesions
could become invasive. Current treatment options for DCIS include breast- conserving surgery and radiation therapy with or without tamoxifen, breast-conserving surgery without radiation therapy, or total mastectomy with or without tamoxifen.
According to the American Cancer Society, in 2014 there were an estimated 51,933 diagnoses of DCIS.
3
Prospectus No. 1
Gastric Cancer
: Gastric cancer (also known as stomach cancer) is a disease in which the
cells forming the inner lining of the stomach become abnormal and start to divide uncontrollably, forming a cancerous tumor mass. Cancer can develop in any of the five sections of the stomach. Symptoms and outcomes of the disease will vary depending
on the location of the cancer. Stomach cancer is one of the leading causes of cancer deaths in several areas of the world, most notably in Asia. Annually, almost one million people will be diagnosed worldwide with stomach cancer and over 700,000
will die from the disease. More than 90% of stomach cancers are caused by adenocarcinomas, malignant cancers that originate in glandular tissues. Overexpression of the HER2 receptor occurs in approximately 20% of gastric and gastro-esophageal
junction adenocarcinomas, predominantly those of the intestinal type. Overall, without regard to the stage of cancer, only approximately 28% of patients with stomach cancer live at least five years following diagnosis and new adjuvant treatments are
needed to prevent disease recurrence.
We currently have a number of ongoing or planned clinical trials designed to expand the clinical
and geographical footprint of NeuVax:
|
|
|
Phase 3 Ongoing: Our Phase 3 PRESENT (
P
revention of
R
ecurrence in
E
arly-
S
tage, Node-Positive Breast Cancer with Low to Intermediate HER2
E
xpression with
NeuVax T
reatment) study
targeted enrollment of 700 HER2 1+/2+ patients under a Special Protocol Assessment (SPA) granted by the U.S. Food and Drug Administration (FDA). The multinational, multicenter, randomized, double-blinded PRESENT trial is ongoing in North
America, Western and Eastern Europe, and Israel. The trial is fully enrolled with 758 patients.
|
|
|
|
Phase 2b Ongoing: A randomized, multicenter, investigator-sponsored, 300 patient Phase 2b clinical trial is enrolling HER2 1+/2+ node-positive and high-risk node-negative breast cancer patients who are HLA A2+, A3+,
A24+ or A26+ to study NeuVax in combination with trastuzumab in the adjuvant setting. This trial is co-funded by Genentech/Roche (providing both trastuzumab and monetary support) and Galena (providing NeuVax and monetary support).
|
|
|
|
Phase 2 Ongoing: An investigator-sponsored trial is ongoing to study NeuVax in combination with trastuzumab. The study will enroll 100 node positive and negative HER2 IHC 3+ patients or HER2 gene-amplified breast cancer
patients who are HLA A2+ or HLA A3+ and are determined to be at high-risk for recurrence. Partial funding for this trial comes from the Department of Defense (DoD) through the Congressionally Directed Medical Research Program via legislation known
as the Defense Appropriations Act. The grant was awarded under a Breast Cancer Research Program with the Breakthrough Award given to the lead investigator for the trial.
|
|
|
|
Phase 2 Planned: A clinical trial, entitled, VADIS: Phase 2 trial of the Nelipepimut-S Peptide
VA
ccine in Women with
D
C
IS
of the Breast is planned to initiate by the end of 2015/early 2016. The
Phase 2 trial will be a single-blind, double arm, randomized, controlled trial in pre- or post-menopausal patients with DCIS and are HLA-A2 positive. VADIS will be co-funded and run in collaboration with the National Cancer Institute (NCI).
|
|
|
|
Phase 2 Planned: A Phase 2 clinical trial in patients with gastric cancer is expected to initiate in 2016. The trial will be run in India by our partner, Dr. Reddys Laboratories, Ltd., as part of our NeuVax
commercialization agreement in that region with Dr. Reddys.
|
GALE-301 and GALE-302
Our second immunotherapy franchise targets folate binding protein receptor-alpha, a well-validated therapeutic target, which is highly
over-expressed (20-80 fold) in ovarian, endometrial and breast cancers. Both GALE-301 (E39) and GALE-302 (E39) are immunogenic peptides that can stimulate CTLs to recognize and destroy FBP-expressing cancer cells. GALE-301 consists of the FBP
peptide E39 combined with GM-CSF, and is currently in a Phase 2a clinical trial for the prevention of recurrence in patients with ovarian and endometrial cancers. GALE-302 is an attenuated version of the E39 peptide and is currently in a Phase 1b
randomized, single-center trial investigating a novel vaccination series using GALE-301 and GALE-302 to evaluate the immune response and monitor long-term immunity. Current treatments after surgery for these diseases are principally with platinum
based chemotherapeutic agents and patients suffer a high recurrence rate; and, most patients relapse with an extremely poor prognosis. Although not powered for efficacy, promising preliminary results from the Phase 2a clinical trial of GALE-301 were
presented in September 2015 at the European Cancer Congress and demonstrated statistically significant data with the estimate for disease free survival at two years at 85.7% (1000 mcg dose group) vs. 33.6% for the control group (p < .02), and
that GALE-301 was well-tolerated with primarily Grade 1 and 2 toxicities and elicited a strong
in vivo
immune response.
In November 2015, we presented preliminary data at the Society for Immunotherapy of Cancer Conference on the primary vaccine series (PVS) from
a randomized Phase lb trial with GALE-301 and GALE-302 demonstrating that the in vivo immune response is enhanced with the use of the attenuated E39 (GALE-302) after E39 (GALE-301). Both agents were shown to be immunogenic and well tolerated
with no differences in toxicities between primary vaccine sequences.
Ovarian and Endometrial Cancer
: According to the NCI
Surveillance, Epidemiology, and End Results (SEER) Program, new cases of ovarian cancer occur at an annual rate of 12.1 per 100,000 women in the U.S., with an estimated 21,290 cases for 2015. Although ovarian cancer represents about 1.3% of all
cancers, it represents about 2.4% of all cancer deaths, or an estimated 14,180 deaths in 2015. Approximately 1.3% of women will be diagnosed with ovarian cancer at
4
Prospectus No. 1
some point during their lifetime (2010 2012 data). The prevalence of ovarian cancer in the U.S. is about 192,000 women, and the five-year survivorship for women with ovarian cancer is
45.6%. Due to the lack of specific symptoms, the majority of ovarian cancer patients are diagnosed at later stages of the disease, with an estimated 75% of women presenting with advanced-stage (III or IV) disease. These patients have their
tumors routinely surgically debulked to minimal residual disease, and then are treated with platinum- and/or taxane-based chemotherapy. While many patients respond to this treatment regimen and become clinically free-of-disease, the majority of
these patients will relapse. Depending upon their level of residual disease, the risk for recurrence after completion of primary therapy ranges from 60% to 85%. Unfortunately for these women, once the disease recurs, treatment options are limited
and the disease remains incurable.
According to the NCI SEER Program, new cases of endometrial cancer occur at an annual rate of
25.1 per 100,000 women in the U.S., with an estimated 54,870 cases for 2015. Although endometrial cancer represents about 3.3% of all cancers, it represents about 1.7% of all cancer deaths, or an estimated 10,170 deaths in 2015. Approximately
2.8% of women will be diagnosed with endometrial cancer at some point during their lifetime (2010 2012 data). The prevalence of endometrial cancer in the U.S. is about 620,000 women, and the five-year survivorship for women with endometrial
cancer is 81.7%.
Hematology
GALE-401 (anagrelide controlled release (CR))
In January 2014, we announced the acquisition of the worldwide rights to anagrelide controlled release (CR), which we renamed GALE-401, through
our acquisition of Mills Pharmaceuticals, LLC. GALE-401 contains the active ingredient anagrelide, an FDA-approved product, for the treatment of patients with myeloproliferative neoplasms (MPNs) to lower abnormally elevated platelet levels. The
currently available immediate release (IR) version of anagrelide causes adverse events that are believed to be dose and plasma concentration dependent. Therefore, reducing the maximum concentration (Cmax) is hypothesized to reduce the side effects,
but preserve efficacy.
Multiple Phase 1 studies in 98 healthy subjects have shown GALE-401 reduces the Cmax of anagrelide following oral
administration, appears to be well-tolerated at the doses administered, and to be capable of reducing platelet levels. The Phase 1 program provided the desired PK/PD (pharmacokinetic/pharmacodynamic) profile to enable the initiation of the ongoing
Phase 2 proof-of-concept trial. The Phase 2, open label, single arm, proof-of-concept trial enrolled 18 patients in the United States for the treatment of thrombocytosis, or elevated platelet counts in patients with MPNs. Phase 2 top-line safety and
efficacy data was presented in June 2015 at the European Hematology Association 20
th
Congress, and we expect to present a more mature data set at the 57th American Society of Hematology Annual
Meeting in December 2015. Based on a regulatory meeting with the FDA, Galena believes a 505(b)(2) regulatory filing is an acceptable pathway for development and potential approval of GALE-401.
Myeloproliferative neoplasms: MPNs are a closely related group of hematological malignancies in which the bone marrow cells that produce the
bodys blood cells develop and function abnormally. The main MPNs are Polycythemia Vera (PV), Essential Thrombocythemia (ET), Primary Myelofibrosis (PMF), and Chronic Myelogenous Leukemia (CML), all of which are associated with high platelet
counts. The MPNs are progressive blood cancers that can strike anyone at any age, and for which there is no known cure.
Strategic Review of
Commercial Operations
During the quarter ended September 30, 2015, we completed a strategic review of the commercial business
and operations. As a result of the review, we recently sold our Abstral
®
(fentanyl) Sublingual Tablets product and related assets, and we are pursuing the sale or other disposition of our
Zuplenz
®
(odansetron) Oral Soluble Film product and related assets described below.
Abstral
®
(fentanyl) Sublingual Tablets
On November 19, 2015, we and Sentynl Therapeutics Inc., or Sentynl, entered into an asset purchase agreement pursuant to which we sold to
Sentynl our Abstral
®
(fentanyl) Sublingual Tablets product and related assets, including our rights in the asset purchase agreement and the license agreement between us and Orexo AB dated
March 15, 2013, and March 18, 2013, respectively, and the settlement and license agreement among Orexo AB, Actavis Laboratories FL, Inc, and us dated October 23, 2015. Sentynl has assumed our future obligations under the Orexo agreements,
except that we will continue to be responsible for certain product channel liabilities. We also will continue to be responsible for any pre-closing liabilities and obligations related to Abstral.
Under the purchase agreement we received from Sentynl an $8 million upfront cash payment and are entitled to up to an aggregate of
$4 million in future cash payments based on Sentynls achievement of specified Abstral net sales milestones. The purchase agreement also includes customary representations, warranties, covenants and indemnities by Sentynl and us.
Zuplenz
®
(ondansetron) Oral Soluble Film
Zuplenz
®
(ondansetron) Oral Soluble Film, is approved by the FDA in adult patients for
the prevention of highly and moderately emetogenic chemotherapy-induced nausea and vomiting (CINV), radiotherapy-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV). Zuplenz is also approved in pediatric patients
treated with moderately emetogenic
5
Prospectus No. 1
CINV. Nausea and vomiting are two of the most common side-effects experienced by post-surgery patients and patients receiving chemotherapy or radiation. Zuplenz utilizes MonoSols
proprietary PharmFilm
®
technology, an oral soluble film that dissolves on the tongue in less than 30 seconds, therefore eliminating the burden of swallowing pills during periods of emesis. The
active pharmaceutical ingredient in Zuplenz, ondansetron, belongs to a class of medications called serotonin 5-HT3 receptor antagonists and works by blocking the action of serotonin, a natural substance that may cause nausea and vomiting.
Alliance Partners in Therapeutic Areas
We are actively looking to leverage our technology platforms by seeking to work with pharmaceutical and biotechnology partners in a number of
therapeutic areas in oncology. Our team has experience targeting products in multiple indications, and based on this experience, we believe we can expand the clinical utility of our current development candidates as well as discover more drug
candidates by working with partners than we can develop with our own resources. We are seeking to work with partners in the discovery and development of drugs in a number of therapeutic areas and technology platforms.
Intellectual Property
Patents and other
intellectual property rights are crucial to our success. It is our policy to protect our intellectual property rights through available means, including filing and prosecuting patent applications in the U.S. and other countries, protecting trade
secrets, and utilizing regulatory protections such as data exclusivity. We also include restrictions regarding use and disclosure of our proprietary information in our contracts with third parties, and utilize customary confidentiality agreements
with our employees, consultants, clinical investigators and scientific advisors to protect our confidential information and know-how. Together with our licensors, we also rely on trade secrets to protect our combined technology especially where we
do not believe patent protection is appropriate or obtainable. It is our policy to operate without infringing on, or misappropriating, the proprietary rights of others. The following chart summarizes our intellectual property rights:
6
Prospectus No. 1
|
|
|
|
|
|
|
|
|
Drug Candidate
|
|
Indication
|
|
Scope
|
|
Strategic Partner
|
|
Estimated
Exclusivity
Period
|
NeuVax (nelipepimut-S)
|
|
Breast cancer recurrence
|
|
Filed and pending or issued
worldwide
|
|
University of
Texas/MDACC/
Henry M. Jackson
Foundation
|
|
2028
|
|
|
|
|
|
NeuVax (nelipepimut-S)
|
|
Gastric
|
|
Filed and pending or issued
worldwide
|
|
Dr. Reddys
Laboratories
|
|
2028
|
|
|
|
|
|
NeuVax (nelipepimut-S)
|
|
DCIS
|
|
Filed and pending or issued
worldwide
|
|
National Cancer
Institute/
University of
Texas, MD
Anderson Cancer
Center
|
|
2028
|
|
|
|
|
|
NeuVax in combination with Herceptin®
|
|
Breast cancer
|
|
Filed and pending or issued
worldwide
|
|
Henry M. Jackson
Foundation,
Genentech/Roche
|
|
2026
|
|
|
|
|
|
NeuVax in combination with other compounds
|
|
Breast cancer
|
|
Filed and pending or issued
worldwide
|
|
Pending
|
|
2037
|
|
|
|
|
|
GALE-301 & GALE-302
|
|
Breast, ovarian and endometrial cancer
|
|
Filed and pending or issued
worldwide
|
|
Henry M. Jackson
Foundation
|
|
2035
|
|
|
|
|
|
GALE-401 (Anagrelide Controlled Release)
|
|
Platelet Lowering
|
|
Filed and pending or issued
worldwide
|
|
BioVascular, Inc.
|
|
2029
|
Out-License Agreements
Teva Pharmaceuticals
Effective December 3, 2012, we entered into a license and supply agreement with ABIC Marketing Limited, a subsidiary of Teva
Pharmaceuticals (ABIC). Under the agreement, we granted ABIC exclusive rights to seek marketing approval in Israel for our NeuVax product candidate for the treatment of breast cancer following its approval by the FDA or the European
Medicines Agency, and to market, sell and distribute NeuVax in Israel assuming such approval is obtained. ABICs rights also include a right of first refusal in Israel for all future indications for which NeuVax may be approved.
Under the license and supply agreement, ABIC will assume responsibility for regulatory registration of NeuVax in Israel, provide financial
support for local development, and commercialize the product in the region in exchange for making royalty payments to us based on future sales of NeuVax. ABIC also agrees in the license and supply agreement to purchase all supplies of NeuVax from us
at a price determined according to a specified formula.
Dr. Reddys Laboratories Ltd.
Effective January 14, 2014, we entered into a strategic development and commercialization partnership with Dr. Reddys
Laboratories Ltd. (Dr. Reddys), under which we licensed commercial rights in India to Dr. Reddys for NeuVax in breast and gastric cancers. Under the agreement, Dr. Reddys will lead the Phase 2 development of
NeuVax in India in gastric cancer, significantly expanding the potential patient population addressable with NeuVax.
Kwangdong
Pharmaceutical Co., Ltd.
Effective April 30, 2009, we entered into a license agreement with Kwangdong Pharmaceutical Co, Ltd
(Kwangdong). Under the agreement, we granted Kwangdong exclusive rights to seek marketing approval in The Republic of Korea (South Korea) for our NeuVax product candidate for the treatment of breast cancer following its approval by the FDA or the
European Medicines Agency, and to market, sell and distribute NeuVax in South Korea assuming such approval is obtained.
Recent Developments (in
reverse chronological order)
Litigation Settlement
On December 4, 2015, we reported that we had reached an agreement in principle to settle the consolidated shareholder derivative
action, captioned
In re Galena Biopharma, Inc. Derivative Litigation,
Civil Action No. 3:14-cv-00382-SI, currently pending in the United States District Court for the District of Oregon against the Company and/or certain of its
current and former officers and directors and the consolidated securities putative class action lawsuits, captioned
In re Galena Biopharma, Inc. Securities Litigation
, Civil Action No. 3:14-cv-00367-SI, pending against the
Company, certain of its current and former officers and directors, and other defendants in the United States District Court for the District of Oregon.
Strategic Review of Commercial Operations
We have completed a strategic review of our commercial operations.
During the three months ended September 30, 2015, we completed a strategic review of the commercial business and operations. As a result
of the review, we recently sold our Abstral
®
(fentanyl) Sublingual Tablets product and related assets, and we have determined to sell or otherwise dispose of our Zuplenz
®
(odansetron) Oral Soluble Film product and related assets and to cease our commercial operations.
GALE-302 Immunological Data Optimizing GALE-301 Presented
- We presented preliminary immunologic data for our GALE-301 and
GALE-302 Phase 1b clinical trial at the Society for Immunotherapy of Cancer (SITC) 30th Anniversary Annual Meeting.
On November 7,
2015 we presented the poster, entitled, Preliminary report of a clinical trial supporting the sequential use of an attenuated E39 peptide (E39) to optimize the immunologic response to the FBP (E39+GM-CSF) vaccine, that compared
three primary vaccine series (PVS) sequences of GALE-301 (E39) and GALE-302 (E39) in ovarian and breast cancer patients to optimize the ex vivo immune responses, local reactions (LR), and delayed type hypersensitivity (DTH) reactions. The data
demonstrated that the in vivo immune response is enhanced with the use of the attenuated E39 (GALE-302) after E39 (GALE-301). The optimal vaccination sequence utilizing three inoculations of GALE-301 followed by three inoculations of GALE-302
produced the most prominent and statistically significant LR and DTH responses.
Patent Infringement Litigation
We
have settled the patent infringement litigation involving Abstral.
On October 27, 2015, we reported that on October 23,
2015 we, Orexo AB and Actavis Laboratories Fl, Inc. (Actavis) had entered into a settlement and license agreement, which will permit Actavis to enter the market with a generic or authorized generic version of Abstral in June 2018 or
earlier under certain circumstances. The litigation, Orexo AB v. Actavis Laboratories FL, Inc., CA
7
Prospectus No. 1
No. 3:15-cv-00826, was dismissed with prejudice by the United States District Court for the District of New Jersey before and the agreement will be filed with the Federal Trade Commission
and the Department of Justice under applicable law.
Collaboration with the National Cancer Institute
We announced a
Phase 2 clinical trial with NeuVax in Ductal Carcinoma in Situ Patients.
On September 30, 2015, we announced a collaboration
with the National Cancer Institute (NCI) to initiate a Phase 2 clinical trial with NeuVax in patients diagnosed with Ductal Carcinoma in Situ (DCIS). The trial will be entitled VADIS: Phase 2 trial of the Nelipepimut-S Peptide Vaccine in Women with
DCIS of the Breast
.
The University of Texas M.D. Anderson Cancer Center (MDACC) Phase I and II Chemoprevention Consortium will be the lead clinical trial site for this multi-center trial with Elizabeth Mittendorf, M.D., Ph.D. serving as the
study Principal Investigator. The Consortium is funded through the Division of Cancer Prevention at NCI, which will provide financial and administrative support for the trial. We will provide NeuVax, as well as additional financial and
administrative support. The single-blind, double arm, randomized, controlled trial is expected to initiate in the fourth quarter of 2015/ first quarter of 2016.
GALE-301 Phase 2a Clinical Trial Data Presented
We announced positive data for our GALE-301 Phase 2a clinical trial
On September 28, 2015 we announced the poster presentation of positive data from the GALE-301 Phase 2a portion of the Phase
1/2a clinical trial at the European Cancer Congress 2015, providing updated data for all ovarian and endometrial cancer patients who have received at least twelve months of treatment on the study. The poster was entitled, entitled
Preliminary results of the phase I/IIa dose finding trial of a folate binding protein vaccine GALE-301 (E39) + GM-CSF in ovarian and endometrial cancer patients to prevent recurrence, and as presented, the clinical recurrence rate based
on all treatment cohorts was 41% in the Vaccine Group (VG) (n=29) versus 55% in the Control Group (CG) (n=22), p=0.41. However, in the 1000 mcg VG cohort (n=15), there have only been two clinical recurrences (13.3% versus 55% CG, p=0.02), and
the two-year Disease Free Survival (DFS) estimate is 85.7% (1000 mcg patients) versus 33.6% (CG), p < 0.02, as compared by Kaplan-Meir and Log rank tests.
IDMC Provides Recommendation to Reduce Cardiac Monitoring in the PRESENT Trial
We announced that the Independent Data
Monitoring Committee (IDMC) for the NeuVax Phase 3 clinical trial recommended to the Company that it can reduce the cardiac toxicity monitoring for patients in our PRESENT study
On August 24, 2015 we announced that the Independent Data Monitoring Committee (IDMC) for the NeuVax Phase 3 clinical trial recommended
to the Company that we can reduce the cardiac toxicity monitoring for patients in our PRESENT study. Following its most recent meeting in June 2015, the IDMC recommended routine cardiac monitoring could be reduced in the PRESENT trial and that such
a reduction is justified and consistent with the pre-specified Cardiac Toxicity Monitoring Stopping Rules defined in the study protocol. The IDMC concluded that cardiac toxicity monitoring by echocardiogram (ECHO) or multiple-gated acquisition
(MUGA) scans could be reduced. The IDMC had no other suggestions and recommended the trial continue as planned.
GALE 401 Phase 2
Clinical Trial Data Presented
- We presented data from our Phase 2 clinical trial of GALE-401 at the European Hematology Association 20th Congress
On June 15, 2015, we announced our poster presentation entitled Phase 2 Study of a Novel Controlled-Release Formulation of
Anagrelide (GALE-401) in Subjects with Myeloproliferative Neoplasm (MPN)-Related Thrombocytosis, which was presented on June 13, 2015. The Phase 2 study demonstrated that GALE-401 was well tolerated with primarily Grade 1 and 2
toxicities in 16 of the 18 subjects enrolled. The efficacy shown in the trial compares favorably to historical anagrelide immediate release (IR) response rates with the following platelet response: overall response rate (ORR) of 78% (14/18);
complete response (CR) of 39% (7/18); partial response (PR) of 39% (7/18). The median time to response was 5 weeks (range, 3-10), and the median duration of response has not yet been reached.
Published Abstracts related to GALE-301 and Leica Biosystems Companion Diagnostic
- We presented two abstract publications
at the American Society of Clinical Oncology (ASCO) 2015 Annual Meeting.
On May 27, 2015, we announced two abstract
publications at the ASCO 2015 Annual Meeting related to our cancer immunotherapy programs:
We presented data related to GALE-301 in
abstract #e14031, entitled, Preliminary Results of the Phase I/IIa Dose Finding Trial of a Folate Binding Protein Vaccine (E39+GM-CSF) in Ovarian and Endometrial Cancer Patients to Prevent Recurrence. The more mature data set from this
trial was presented in September 2015 as mentioned above.
8
Prospectus No. 1
We presented data related to our NeuVax Phase 3 PRESENT trial companion diagnostic in abstract
#e11609, entitled, Analytical Validation of BOND Oracle HER2 IHC System for Identifying Low to Intermediate HER2 Expressing Breast Cancer in NeuVax PRESENT Phase 3 Clinical Trial. This data demonstrated a direct correlation between cell
line receptor load, quantitative measure of HER2 protein, and IHC score. The ability to discriminate HER2 protein expression at the low and intermediate levels in breast cancer tumors will identify patients for new treatments in development such as
NeuVax. Specifically, the validation of the Bond Oracle HER2 IHC System to distinguish lower levels of HER2+ expressions supports its use as a companion diagnostic.
NeuVax Phase 3 PRESENT Over-Enrollment Completed
- We announced the completion of enrollment in our NeuVax Phase 3 PRESENT
clinical trial.
On April 14, 2015, we announced the completion of enrollment in the NeuVax Phase 3 PRESENT clinical
trial. As anticipated, we over-enrolled the trial by 7.7% with a total of 758 patients now in the intent-to-treat (ITT) population. The protocol for the PRESENT trial called for 700 patients; and we expect this higher number of ITT patients will
increase the confidence in both the timing and quality of the statistics and the final outcome of the trial. The primary endpoint is currently expected to be reached in 2018, after the last patient dosed reaches her 36th month of treatment, or a
total of 141 events (recurrence or death) occur, whichever comes later.
Expanded Patient Population in NeuVax Combination
Trial
- We announced the expansion of the patient population in the NeuVax and trastuzumab combination trial in HER2 1+/2+ patients to include HLA A24+ or HLA-A26+ patients.
On March 26, 2015, we announced that human leukocyte antigen (HLA) - A24+ or HLA-A26+ women are now eligible for enrollment into the
ongoing Phase 2b clinical trial with NeuVax in combination with trastuzumab. The trial evaluates node positive and triple negative, node negative breast cancer patients with immunohistochemistry (IHC) HER2 1+/2+ expressing tumors who are
disease-free after standard of care therapy.
Enrolled 700th Patient in NeuVax Phase 3 PRESENT Clinical Trial
We
announced enrollment of the 700th patient in our Phase 3 PRESENT clinical trial.
On February 9, 2015, we announced the
enrollment in the NeuVax Phase 3 PRESENT clinical trial of the 700th patient, which is the patient enrollment target as defined by the PRESENT Phase 3 clinical trial protocol.
Financial Condition
We had cash and cash
equivalents of approximately $34.8 million as of September 30, 2015. We believe that our existing cash and cash equivalents together with funding available under our purchase agreement with Lincoln Park Capital Fund, LLC and sales agreements
with MLV & Co. and Maxim Group LLC should be sufficient to fund our operations for at least one year. This projection is based on our current planned operations and revenue expectations and is subject to changes in our plans and
uncertainties inherent in our business, and we may need to seek to replenish our existing cash and cash equivalents sooner than we project. There is no guarantee that any additional funding will be available to us on acceptable terms, or at all. If
we fail to obtain additional funding when needed, we would be forced to scale back or terminate our operations, or to seek to merge with or to be acquired by another company.
Purchase Agreement with Lincoln Park Capital Fund, LLC
On November 18, 2014, we entered into a purchase agreement with Lincoln Park Capital Fund, LLC, or Lincoln Park. The purchase agreement
provides that in our discretion, upon the terms and subject to the conditions and limitations set forth therein, Lincoln Park currently is irrevocably committed to purchase from us an aggregate of up to $42,194,000 of additional shares of our common
stock over the remaining term of the purchase agreement.
There is no upper limit on the price per share that Lincoln Park must pay for
our common stock under the purchase agreement, but in no event will shares be sold to Lincoln Park on a day our closing price is less than $1.00 per share. The purchase price will be equitably adjusted for any reorganization, recapitalization,
non-cash dividend, stock split or other similar transaction occurring during the business days used to compute the purchase price.
There
are no trading volume requirements or restrictions under the purchase agreement, but there are limitations on the number of shares we can sell to Lincoln Park as described below. We will control the timing and amount of any sales of our common stock
to Lincoln Park, and we may terminate the purchase agreement at any time without fee, penalty or cost, upon one business day notice to Lincoln Park.
The purchase agreement limits our sales of shares of common stock to Lincoln Park to a maximum of 19.99% of our total outstanding shares of
common stock as of November 18, 2014, or approximately 42,270,277 shares, including 7,932,121 shares sold
9
Prospectus No. 1
to Lincoln Park prior to the date of this prospectus, unless we first obtain stockholder approval under the rules of The NASDAQ Capital Market or unless the average price of all shares of our
common stock sold to Lincoln Park exceeds $1.889, which represents the closing bid price of our common stock on November 18, 2014 as reported on The NASDAQ Capital Market plus $0.0491, such that such sales to Lincoln Park are considered to be
at least at market under the applicable NASDAQ rules.
The purchase agreement also prohibits us from selling Lincoln Park any
shares of common stock if those shares, when aggregated with all other shares of our common stock then beneficially owned by Lincoln Park and its affiliates, would result in Lincoln Park and its affiliates having beneficial ownership of more than
9.99% of the then total outstanding shares of our common stock (approximately 16,174,000 shares as of September 30, 2015), as calculated pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and
Rule 13d-3 thereunder.
Sales Agreements with MLV & Co. and Maxim Group LLC
We entered into sales agreements with MLV & Co. LLC, or MLV, and Maxim Group LLC, or Maxim, on May 24, 2013, under which we may
currently issue and sell our common stock having a cumulative aggregate offering price of up to $20,000,000.
The sales, if any, of shares
made under the sales agreements will be made on The NASDAQ Capital Market by means of ordinary brokers transactions at market prices, in block transactions or as otherwise agreed by MLV or Maxim and us. We may instruct MLV and Maxim not to
sell common stock if the sales cannot be effected at or above the price designated by us from time to time. We or MLV or Maxim may suspend the offering of common stock upon notice and subject to other conditions. As agents, MLV and Maxim will not
engage in any transactions that stabilize the price of our common stock.
We will pay each of MLV and Maxim commissions for its services
in acting as agent in the sale of common stock. MLV and Maxim will be entitled to compensation at a fixed commission rate of 3.0% of the gross sales price per share sold.
Corporate Information
Our principal
executive offices are located at 2000 Crow Canyon Place, Suite 380, San Ramon, California 94583, and our phone number is (855) 855-4253. Our website address is www.galenabiopharma.com. We do not incorporate the information on our website into
this prospectus, and you should not consider such information part of this prospectus.
We were incorporated as Argonaut Pharmaceuticals,
Inc. in Delaware on April 3, 2006 and changed our name to RXi Pharmaceuticals Corporation on November 28, 2006. On September 26, 2011, we changed our company name from RXi Pharmaceuticals Corporation to Galena Biopharma, Inc.
USE OF PROCEEDS
Unless we state otherwise in the accompanying prospectus supplement, we currently intend to use the net proceeds from this offering to augment
our working capital and for general corporate purposes, including our Phase 3 PRESENT study and other clinical trials of our product candidates. General corporate purposes also may include, but are not limited to, payments relating to the
ongoing defense or settlement of pending stockholder lawsuits or the possible sale or other disposition of our marketed products and discontinuation of our commercial operations, repayment of indebtedness, financing of capital expenditures and
potential future acquisitions and strategic investments. Pending application of the net proceeds, we expect to invest the net proceeds in
investment-grade,
interest-bearing securities.
10
Prospectus No. 1
FINANCIAL RATIOS
We present below the ratio of our earnings to combined fixed charges and preference dividends, if any. Earnings consist of our net loss plus
fixed charges. Fixed charges consist of interest expense and amortization of debt issuance costs. We recorded no preference dividends in any of the periods presented.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
Nine
Months
Ended
September
30,
|
|
|
|
2010
|
|
|
2011
|
|
|
2012
|
|
|
2013
|
|
|
2014
|
|
|
2015
|
|
Ratio of earnings (loss) to combined fixed charges and preference dividends(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Deficiency in earnings (loss) to cover fixed charges
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
N/A
|
|
(1)
|
We did not record earnings in any of the periods presented. Accordingly, our earnings were insufficient to cover fixed charges in such periods, and we are unable to disclose a ratio of earnings to combined fixed charges
and preference dividends for such periods.
|
THE SECURITIES THAT
WE MAY OFFER
We, directly or through agents, dealers or underwriters designated from time to time, may offer, issue and sell,
together or separately, up to $100,000,000 in the aggregate of:
|
|
|
shares of our common stock, par value $0.0001 per share;
|
|
|
|
shares of our preferred stock, par value $0.0001 per share;
|
|
|
|
warrants to purchase our common stock or preferred stock;
|
|
|
|
rights to purchase our common stock or preferred stock; and
|
|
|
|
any combination of the securities listed above, separately or as units, each on terms to be determined at the time of sale.
|
The common stock, preferred stock, warrants, rights and units collectively are referred to in this prospectus as the securities.
We have summarized below the material terms of the various types of securities that we may offer. We will describe in the applicable
prospectus supplement the detailed terms of the securities offered by that supplement. If indicated in the prospectus supplement, the terms of the offered securities may differ from the terms summarized below.
DESCRIPTION OF CAPITAL STOCK
General
Our authorized capital stock
consists of 280,000,000 shares, all which includes:
|
|
|
275,000,000 shares of common stock, par value $0.0001 per share, and
|
|
|
|
5,000,000 shares of preferred stock, par value $0.0001 per share.
|
As of September 30,
2015, there were 161,900,446 shares of common stock outstanding held by approximately 544 stockholders of record, and no shares of preferred stock outstanding. The number of holders of record does not include shares held in street name
through brokers.
11
Prospectus No. 1
Common Stock
Each holder of our common stock is entitled to one vote for each share of common stock held on all matters submitted to a vote of stockholders.
Common stockholders are not entitled to cumulative voting in the election of directors by our certificate of incorporation. This means that the holders of a majority of the shares voted will be able to elect all of the directors then standing for
election. Subject to preferences that may apply to shares of preferred stock outstanding at the time, the holders of outstanding shares of our common stock are entitled to receive dividends out of assets legally available at the times and in the
amounts that our board of directors may determine from time to time.
Upon our liquidation, dissolution or winding-up, the holders of our
common stock will be entitled to share ratably in all assets remaining after payment of all liabilities and the liquidation preferences of any series of capital stock ranking senior to the common stock upon liquidation. Holders of common stock have
no preemptive or conversion rights or other subscription rights. There will be no redemption or sinking fund provisions applicable to the common stock. All outstanding shares of common stock are fully paid and nonassessable, and the shares of common
stock to be issued under this prospectus, when they are paid for, will be fully paid and nonassessable.
Preferred Stock
Our board of directors is authorized, subject to any limitations prescribed by law, without further vote or action by the stockholders, to
issue from time to time any of the authorized shares of preferred stock in one or more series without stockholder approval. Each such series of preferred stock shall have such number of shares, designations, preferences, voting powers,
qualifications, and special or relative rights or privileges as shall be determined by our board of directors, which may include, among others, dividend rights, voting rights, liquidation preferences, conversion rights and preemptive rights.
Our board of directors will fix the rights, preferences, privileges, qualifications and restrictions of the preferred stock of each series
that we sell under this prospectus in the certificate of designation relating to each such series. We will incorporate by reference as an exhibit to the registration statement of which this prospectus is a part or as an exhibit to one or more
current reports on
Form 8-K,
the form of any certificate of designation that describes the terms of the series of preferred stock we are offering before the issuance of the related series of preferred
stock. This description will include:
|
|
|
the title and stated value;
|
|
|
|
the number of shares we are offering;
|
|
|
|
the liquidation preference per share;
|
|
|
|
the purchase price per share;
|
|
|
|
the dividend rate per share, dividend period, payment date or dates and method of calculation of dividends;
|
|
|
|
whether dividends will be cumulative or non-cumulative and, if cumulative, the date from which dividends will accumulate;
|
|
|
|
our right, if any, to defer payment of dividends and the maximum length of any such deferral period;
|
|
|
|
the procedures for any auction and remarketing, if any;
|
|
|
|
the provisions for a sinking fund, if any;
|
|
|
|
the provisions for redemption or repurchase, if applicable, and any restrictions on our ability to exercise those redemption and repurchase rights;
|
|
|
|
any listing of the preferred stock on any securities exchange or market;
|
|
|
|
whether the preferred stock will be convertible into our common stock or other securities of ours, including warrants, and, if applicable, the conversion price, or how it will be calculated, and under what circumstances
and the mechanism by which it may be adjusted, and the conversion period;
|
|
|
|
whether the preferred stock will be exchangeable into debt securities or other securities of ours, and, if applicable, the exchange price, or how it will be calculated, and under what circumstances it may be adjusted,
and the exchange period;
|
|
|
|
preemptive rights, if any;
|
12
Prospectus No. 1
|
|
|
restrictions on transfer, sale or other assignment, if any;
|
|
|
|
a discussion of any material United States federal income tax considerations applicable to the preferred stock;
|
|
|
|
the relative ranking and preferences of the preferred stock as to dividend rights and rights if we liquidate, dissolve or wind up our affairs;
|
|
|
|
any limitations on issuances of any class or series of preferred stock ranking senior or on a parity with the series of preferred stock being issued as to dividend rights and rights if we liquidate, dissolve or wind up
our affairs; and
|
|
|
|
any other specific terms, rights, preferences, privileges, qualifications or limitations of, or restrictions on, the preferred stock.
|
If we issue and sell shares of preferred stock pursuant to this prospectus, the shares will be fully paid and nonassessable and will not have,
or be subject to, any preemptive or similar rights.
The laws of the State of Delaware, the state of our incorporation, provide that the
holders of preferred stock will have the right to vote separately as a class on any proposal involving fundamental changes in the rights of holders of such preferred stock. This right is in addition to any voting rights that may be provided for in
the applicable certificate of designation.
We believe the power to issue preferred stock will provide our board of directors with
flexibility in connection with certain possible corporate transactions. The issuance of preferred stock, however, could adversely affect the voting power of holders of our common stock, restrict their rights to receive payment upon liquidation, and
have the effect of delaying, deferring, or preventing a change in control which may be beneficial to our stockholders.
Anti-Takeover Effects of
Delaware Law and Our Restated Certificate of Incorporation and Bylaws
Certain provisions of Delaware law, our amended and restated
certificate of incorporation and our amended and restated bylaws contain provisions that could have the effect of delaying, deferring or discouraging another party from acquiring control of us. These provisions, which are summarized below, are
expected to discourage certain types of coercive takeover practices and inadequate takeover bids. These provisions are also designed, in part, to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We
believe that the benefits of increased protection of our potential ability to negotiate with an unfriendly or unsolicited acquirer outweigh the disadvantages of discouraging such proposals, including proposals that are priced above the then-current
market value of our common stock, because, among other reasons, the negotiation of such proposals could result in an improvement of their terms.
Certificate of Incorporation and Bylaws
Our amended and restated certificate of incorporation and amended and restated bylaws include provisions that:
|
|
|
authorize our board of directors to issue, without further action by the stockholders, up to 5,000,000 shares of undesignated preferred stock;
|
|
|
|
require that any action to be taken by our stockholders be effected at a duly called annual or special meeting and not by written consent;
|
|
|
|
specify that special meetings of our stockholders can be called only by our board of directors, the chairman of the board or the chief executive officer;
|
|
|
|
provide that our board of directors will be classified, with directors serving staggered three-year terms;
|
|
|
|
provide that directors may be removed only for cause and may only be removed for cause only by the holders of 75% of our outstanding capital stock entitled to vote generally in the election of directors;
|
|
|
|
provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum;
|
|
|
|
provide for a 75% vote of stockholders to amend our amended and restated bylaws, unless the amendment has been approved by a majority of our directors who are not affiliated or associated with any person or entity
holding 10% or more of the voting power of our outstanding capital stock; and
|
13
Prospectus No. 1
|
|
|
establish an advance notice procedure for stockholder proposals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors.
|
Delaware Anti-Takeover Statute
We are subject to the provisions of Section 203 of the Delaware General Corporation Law regulating corporate takeovers. In general,
Section 203 prohibits a publicly-held Delaware corporation from engaging, under certain circumstances, in a business combination with an interested stockholder for a period of three years following the date the person became an interested
stockholder unless:
|
|
|
prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;
|
|
|
|
upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the
transaction commenced, excluding for purposes of determining the voting stock outstanding, but not the outstanding voting stock owned by the interested stockholder, (1) shares owned by persons who are directors and also officers and
(2) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or
|
|
|
|
at or subsequent to the date of the transaction, the business combination is approved by the board of directors of the corporation and authorized at an annual or special meeting of stockholders, and not by written
consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock which is not owned by the interested stockholder.
|
Generally, a business combination includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to
the interested stockholder. Generally, an interested stockholder is a person who, together with affiliates and associates, owns or, within three years prior to the determination of interested stockholder status, did own 15%
or more of a corporations outstanding voting stock. We expect the existence of this provision to have an anti-takeover effect with respect to transactions our board of directors does not approve in advance. We also anticipate that
Section 203 may discourage business combinations or other attempts that might result in a premium over the market price for the shares of common stock held by our stockholders.
The provisions of Delaware law, our restated certificate of incorporation and our amended and restated bylaws could have the effect of
discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions
may also have the effect of preventing changes in our management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests.
Listing
Our common stock is listed on
The NASDAQ Capital Market under the symbol GALE.
Transfer Agent and Registrar
The transfer agent and registrar for our common stock is Computershare Trust Company, N.A.
DESCRIPTION OF WARRANTS
We may issue warrants for the purchase of preferred stock or common stock, or a combination thereof. We may issue warrants independently or
together with any other securities offered by any prospectus and may be attached to or separate from the other offered securities. Each series of warrants will be issued under a separate warrant agreement to be entered into by us with a warrant
agent. The warrant agent will act solely as our agent in connection with the warrants and will not assume any obligation or relationship of agency or trust for or with any holders or beneficial owners of warrants. Further terms of the warrants and
the applicable warrant agreements will be set forth in the applicable prospectus supplement.
The prospectus supplement relating to any
particular issue of warrants will describe the terms of the warrants, including, as applicable, the following:
|
|
|
the title of the warrants;
|
14
Prospectus No. 1
|
|
|
the aggregate number of the warrants;
|
|
|
|
the price or prices at which the warrants will be issued;
|
|
|
|
the designation, terms and number of shares of debt securities, preferred stock or common stock purchasable upon exercise of the warrants;
|
|
|
|
the designation and terms of the offered securities, if any, with which the warrants are issued and the number of the warrants issued with each offered security;
|
|
|
|
the date, if any, on and after which the warrants and the related debt securities, preferred stock or common stock will be separately transferable;
|
|
|
|
the price at which each share of debt securities, preferred stock or common stock purchasable upon exercise of the warrants may be purchased;
|
|
|
|
the date on which the right to exercise the warrants shall commence and the date on which that right shall expire;
|
|
|
|
the minimum or maximum amount of the warrants which may be exercised at any one time;
|
|
|
|
information with respect to book-entry procedures, if any;
|
|
|
|
a discussion of certain federal income tax considerations; and
|
|
|
|
any other terms of the warrants, including terms, procedures and limitations relating to the exchange and exercise of the warrants.
|
We and the warrant agent may amend or supplement the warrant agreement for a series of warrants without the consent of the holders of the
warrants issued thereunder to effect changes that are not inconsistent with the provisions of the warrants and that do not materially and adversely affect the interests of the holders of the warrants.
DESCRIPTION OF RIGHTS
We may issue rights to purchase common stock or preferred stock. The accompanying prospectus supplement will contain the material terms and
conditions for each right.
We will describe in the applicable prospectus supplement the terms and conditions of the issue of rights being
offered, the rights agreement relating to the rights and the rights certificates representing the rights, including, as applicable:
|
|
|
the title of the rights;
|
|
|
|
the date of determining the stockholders entitled to the rights distribution;
|
|
|
|
the title, aggregate number of shares of common stock or preferred stock purchasable upon exercise of the rights;
|
|
|
|
the aggregate number of rights issued;
|
|
|
|
the date, if any, on and after which the rights will be separately transferable;
|
|
|
|
the date on which the right to exercise the rights will commence and the date on which the right will expire; and
|
|
|
|
any other terms of the rights, including terms, procedures and limitations relating to the distribution, exchange and exercise of the rights.
|
Each right will entitle the holder of rights to purchase for cash the principal amount of shares of common stock or preferred stock at the
exercise price provided in the applicable prospectus supplement. Rights may be exercised at any time up to the close of business on the expiration date for the rights provided in the applicable prospectus supplement. After the close of business on
the expiration date, all unexercised rights will be void.
15
Prospectus No. 1
Holders may exercise rights as described in the applicable prospectus supplement. Upon receipt of
payment and the rights certificate properly completed and duly executed at the corporate trust office of the rights agent or any other office indicated in the prospectus supplement, we will, as soon as practicable, forward the shares of common stock
or preferred stock purchasable upon exercise of the rights. If less than all of the rights issued in any rights offering are exercised, we may offer any unsubscribed securities directly to persons other than stockholders, to or through agents,
underwriters or dealers or through a combination of such methods, including pursuant to standby underwriting arrangements, as described in the applicable prospectus supplement.
DESCRIPTION OF UNITS
We may offer and issue units that consist of shares of our common stock or preferred stock and warrants to purchase additional shares of our
common stock or preferred stock. For example, we may elect to issue units for a specified price per unit, with each unit consisting of one share of our common stock or preferred stock and one warrant to purchase an additional share of our common
stock or preferred stock at a specified price. The holder of a unit will also hold each of the securities that is included in the unit.
We have provided in the preceding sections of this prospectus a general description of our common stock, preferred stock, and warrants that we
may offer. If we elect to offer units, we will describe the specific terms of the units in a supplement to this prospectus. Among other things, the prospectus supplement will describe, to the extent applicable:
|
|
|
the price of each unit;
|
|
|
|
the securities comprising each unit;
|
|
|
|
the exercise price of the warrants comprising part of the units;
|
|
|
|
the aggregate number of units offered;
|
|
|
|
the number of shares of common stock or preferred stock that may be purchased upon the exercise of each warrant comprising part of a unit;
|
|
|
|
the terms of any right by us to redeem any of the securities comprising the units;
|
|
|
|
the date on which the right to exercise the warrants forming part of the units will commence and the date on which this right will expire;
|
|
|
|
any transfer restrictions on the units, including whether the securities comprising the units may be transferred separately;
|
|
|
|
the terms on which the units or warrants forming part of the units may be amended;
|
|
|
|
with respect to preferred stock forming part of the units, the other matters listed above under Description of Capital StockPreferred Stock;
|
|
|
|
with respect to warrants forming part of the units, the other matters listed above under Description of Warrants; and
|
|
|
|
the material United States federal income tax consequences applicable to the units.
|
PLAN OF DISTRIBUTION
We may sell the securities offered by this prospectus to one or more
underwriters or dealers for public offering and sale by them or to investors directly or through agents. The accompanying prospectus supplement will set forth the terms of the offering and the method of distribution and will identify any firms
acting as underwriters, dealers or agents in connection with the offering, including:
|
|
|
the name or names of any underwriters, dealers or agents;
|
|
|
|
the purchase price of the securities and the proceeds to us or to any selling stockholder from the sale;
|
|
|
|
any underwriting discounts and other items constituting compensation to underwriters, dealers or agents;
|
|
|
|
any public offering price;
|
16
Prospectus No. 1
|
|
|
any discounts or concessions allowed or reallowed or paid to dealers; and
|
|
|
|
any securities exchange or market on which the securities offered in the prospectus supplement may be listed.
|
Only those underwriters identified in such prospectus supplement are deemed to be underwriters in connection with the securities offered in
the prospectus supplement.
The distribution of the securities may be effected from time to time in one or more transactions at a fixed
price or prices, which may be changed, or at prices determined as the applicable prospectus supplement specifies. The securities may be sold through a rights offering, forward contracts or similar arrangements. In connection with the sale of the
securities, underwriters, dealers or agents may be deemed to have received compensation from us or selling stockholders in the form of underwriting discounts or commissions and also may receive commissions from securities purchasers for whom they
may act as agent. Underwriters may sell the securities to or through dealers, and the dealers may receive compensation in the form of discounts, concessions or commissions from the underwriters or commissions from the purchasers for whom they may
act as agent. Some of the underwriters, dealers or agents who participate in the securities distribution may engage in other transactions with, and perform other services for, us in the ordinary course of business.
We will provide in the applicable prospectus supplement information regarding any underwriting discounts or other compensation that we pay to
underwriters or agents in connection with the securities offering, and any discounts, concessions or commissions which underwriters allow to dealers. Underwriters, dealers and agents participating in the securities distribution may be deemed to be
underwriters, and any discounts and commissions they receive and any profit they realize on the resale of the securities may be deemed to be underwriting discounts and commissions under the Securities Act of 1933. Underwriters and their controlling
persons, dealers and agents may be entitled, under agreements entered into with us, to indemnification against and contribution toward specific civil liabilities, including liabilities under the Securities Act.
The securities may or may not be listed on a national securities exchange. In connection with an offering, the underwriters may purchase and
sell securities in the open market. These transactions may include short sales, stabilizing transactions and purchases to cover positions created by short sales. Short sales involve the sale by the underwriters of a greater number of securities than
they are required to purchase in an offering. Stabilizing transactions consist of bids or purchases made for the purpose of preventing or retarding a decline in the market price of the securities while an offering is in progress. The underwriters
also may impose a penalty bid. This occurs when a particular underwriter repays to the underwriters a portion of the underwriting discount received by it because the underwriters have repurchased securities sold by or for the account of that
underwriter in stabilizing or short-covering transactions. These activities by the underwriters may stabilize, maintain or otherwise affect the market price of the securities. As a result, the price of the securities may be higher than the price
that otherwise might exist in the open market. If these activities are commenced, they may be discontinued by the underwriters at any time.
Any underwriter who is qualified market maker on The Nasdaq Capital Market may engage in passive market making transactions in the securities
on The Nasdaq Capital Market in accordance with Rule 103 of Regulation M, during the business day prior to the pricing of the offering, before the commencement of offers or sales of the securities. Passive market makers must comply with applicable
volume and price limitations and must be identified as passive market makers. In general, a passive market maker must display its bid at a price not in excess of the highest independent bid for such security; if all independent bids are lowered
below the passive market makers bid, however, the passive market makers bid must then be lowered when certain purchase limits are exceeded.
Certain underwriters, dealers or agents and their associates may engage in transactions with and perform services for us in the ordinary
course of our business.
LEGAL MATTERS
TroyGould PC, Los Angeles, California, has rendered an opinion with respect to the securities offered by this prospectus. Sanford J.
Hillsberg, the Chairman of our company, is an attorney with TroyGould PC. TroyGould PC owned 63,941 shares of our common stock as of September 30, 2015.
EXPERTS
The consolidated financial statements of the Company as of December 31, 2014 and 2013, and for the years then ended, and the effectiveness of
internal control over financial reporting of the Company as of December 31, 2014, have been incorporated by reference herein in reliance upon the reports of Moss Adams LLP, independent registered public accounting firm, incorporated by reference
herein, and upon the authority of said firm as experts in accounting and auditing.
17
Prospectus No. 1
The consolidated financial statements of Galena Biopharma, Inc. for the year ended
December 31, 2012 incorporated by reference in this prospectus have been so incorporated in reliance on the report of BDO USA, LLP, an independent registered public accounting firm, incorporated herein by reference, given on the authority of
said firm as experts in auditing and accounting.
WHERE YOU CAN FIND MORE
INFORMATION
We have filed a registration statement on Form S-3 with the SEC under the Securities Act of 1933. This prospectus is part
of the registration statement but the registration statement includes and incorporates by reference additional information and exhibits. We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read
and copy the registration statement and any other document we file with the SEC at the public reference room maintained by the SEC at 100 F Street, N.E., Washington, D.C. 20549. You may obtain information on the operation of the public reference
room by calling the SEC at 1-800-SEC-0330. The SEC also maintains a web site that contains reports, proxy and information statements and other information regarding companies, such as ours, that file documents electronically with the SEC. The
address of that site on the world wide web is http://www.sec.gov. The information on the SECs web site is not part of this prospectus, and any references to this web site or any other web site are inactive textual references only.
INCORPORATIO
N OF CERTAIN DOCUMENTS BY REFERENCE
The SEC allows us to incorporate by reference information from other documents that we file with it, which means that we can
disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus. Information in this prospectus supersedes information incorporated by reference that we
filed with the SEC prior to the date of this prospectus, while information that we file later with the SEC will automatically update and supersede the information in this prospectus. We incorporate by reference into this prospectus and the
registration statement of which this prospectus is a part the information or documents listed below that we have filed with the SEC:
|
|
|
our Annual Report on Form 10-K for the year ended December 31, 2014, which was filed on March 5, 2015, and amended on March 10, 2015 (Items 6, 7, and 8 from said Annual Report have been recast for discontinued
operations as reflected in the Current Report on Form 8-K filed on December 4, 2015);
|
|
|
|
our Quarterly Report on Form 10-Q for the three months ended March 31, 2015 filed with the SEC on May 7, 2015;
|
|
|
|
our Quarterly Report on Form 10-Q for the three months ended June 30, 2015 filed with the SEC on August 6, 2015;
|
|
|
|
our Quarterly Report on Form 10-Q for the three months ended September 30, 2015 filed with the SEC on November 9, 2015;
|
|
|
|
our Current Reports on Form 8-K filed with the SEC on January 14, 2015, February 9, 2015, March 5, 2015, March 16, 2015, April 9, 2015, May 7, 2015, June 24, 2015, August 6, 2015, October 27, 2015, October 30, 2015,
November 20, 2015, and December 4, 2015, respectively; and
|
|
|
|
the description of our common stock contained in our registration statement on Form 8-A (File No. 001-33958) filed pursuant to Section 12 of the Exchange Act, as amended from time to time.
|
We also incorporate by reference into this prospectus all documents filed by us with the SEC pursuant to Sections 13(a), 13(c), 14
or 15(d) of the Securities Exchange Act of 1934 prior to the termination of this offering, including all such documents that we may file with the SEC after the date of the initial registration statement and prior to the effectiveness of the
registration statement, except that we are not incorporating any information furnished under Item 2.02 or Item 7.01 of any Current Report on Form 8-K we may subsequently file.
You may request a copy of the documents incorporated by reference into this prospectus, at no cost, by writing or telephoning us at the
following address:
Galena Biopharma, Inc.
2000 Crow Canyon Place, Suite 380
San Ramon, California 94583
Attention: Investor Relations
Phone: (855) 855-4253
Copies of these documents are also available, without charge, through the Investor Relations section of our website
(www.galenabiopharma.com) as soon as reasonably practicable after it are filed with the SEC. The information contained on our website is not a part of this prospectus.
18
Prospectus No. 1
Shares of Common Stock
Warrants to Purchase Shares of Common Stock
PROSPECTUS SUPPLEMENT
CANACCORD GENUITY
February , 2017
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Apr 2024 to May 2024
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From May 2023 to May 2024